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Abstract 
Background: Medications benefit people with diseases and medical conditions, 
improving many patients' lives and in some cases significantly increasing their quality 
of life. Despite these great benefits, medications can lead to serious adverse effects. 
Adverse drug reactions (ADRs) are the 4th leading cause of death, greater than major 
killers including pulmonary diseases, diabetes and automobile death. Not all 
medication groups have the same incidence in inducing diseases. Anti-infective agents 
- including antibacterial agents- are the most likely to induce diseases followed by 
cardiovascular agents and antineoplastic agents. 
Objectives: Drug safety is a very important issue in patient therapy. Since 
antibacterial agents in general and fluoroquinolones specifically are among the most 
prescribed medications, it is very important to quantify their risks in causing serious 
adverse reactions such as hepatotoxicity and pancreatitis. In terms of drug safety and 
preventing ADRs, costs are a very important factor because many conditions like 
hypoglycemia can be prevented, leading to significant decreases in cost and 
improvement in quality of life. Since there is a dearth of research that has examined 
these areas, epidemiological studies are needed. The objectives of the three proposed 
manuscripts of this dissertation were to a) estimate the risk of hepatotoxicity 
associated with fluoroquinolones use; b) examine antibacterial agents use and the risk 
ofacute pancreatitis development; c) review the healthcare databases in United States 
and European countries that are commonly utilized in conducting epidemiological 
research. 
Methods: Two matched case control studies were used to examine the risk of 
hepatotoxicity and acute pancreatitis development with using fluoroquinolones and 
antibacterial agents, respectively. The Veterans' Affairs (VA) medical database was 
used to perform the two studies. Odds ratios (OR) and their 95% confidence intervals 
(CI) were derived from crude and adjusted conditional logistic regression models. In 
the third paper, a literature search was performed using Publisher Medline (Pubmed), 
Embase® and the Iowa Drug Information Services (IDIS) to perform a review of four 
medical databases including the Nationwide Inpatient Sample database, the Veterans' 
Affairs medical database, the Health Improvement Network database and the 
Norwegian medical database. 
Results: In the first study, fluoroquinolones use was associated with increased risk of 
hepatotoxicity. However, only ciprofloxacin was statistically significantly associated 
with development of hepatotoxicity while levofloxacin and moxifloxacin were not 
associated with hepatotoxicity development. In the second study, use of antibacterial 
agents was associated with increased risk of acute pancreatitis. 
Conclusion: The findings fro in both studies show that antibacterial agents are 
associated with increased risk of hepatotoxicity and acute pancreatitis. Knowing the 
safety of medication is very important for the clinical practice especially for 
antibacterial agents since they are commonly used and clinicians are considering these 
agents very safe. However, further research is needed to confirm these findings and to 
understand the biological mechanism behind their toxicity. 
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Preface 
All three Chapters in this dissertation were prepared following the manuscript format 
for each journal. 
Chapter I: Estimating the Risk ofHepatotoxicity Associated with Fluoroquinolone 
Use: A Case-Control Study Using the National Veterans Affairs Database. The 
Journal of the American Medical Association (JAMA) format 
Chapter II: Antibacterial use and risk of acute pancreatitis: A Case-Control Study 
Using the National Veterans Affairs Database. Clinical Infectious Diseases (CID) 
format 
Chapter III: Review the healthcare databases in United States and European countries 
that are commonly utilized in conducting epidemiologic research. 
Pharmacoepidemiology and Drug Safety (PDS) format. 
vii 
Table of Contents 
Acknowledgement ............................................................................................................... iv 
Preface ....................................................................................................................... vii 
Table of Contents ....................................................................................................................... v111 
List of Tables ....................................................................................................................... x 
Chapter I: Estimating the Risk odf Hepatotoxicity Associated with 
Fluoroquinolone Use: A Case-Control Study Using the National Veterans Affairs 
Database 
Abstract 
Background 
Methods 
Results 
Discussion 
Conclusion 
Tables 
References 
...................................................................................................................... 1 
...................................................................................................................... 2 
...................................................................................................................... 4 
...................................................................................................................... 7 
...................................................................................................................... 11 
...................................................................................................................... 13 
...................................................................................................................... 19 
...................................................................................................................... 20 
....................................................................................................................... 23 
Chapter II: Antibacterial use and risk of acute pancreatitis: A Case-Control 
Study Using the National Veterans Affairs 
Database 
Abstract 
Background 
Methods 
Results 
Discussion 
Conclusion 
Tables 
.............................................. -........................................................................ 31 
....................................................................................................................... 32 
....................................................................................................................... 34 
...................................................................................................................... 37 
...................................................................................................................... 41 
...................................................................................................................... 43 
...................................................................................................................... 49 
..................................................................................................................... 50 
viii 
References ...................................................................................................................... 54 
Chapter III: Review the healthcare databases in United States and European 
countries that are commonly utilized in conducting epidemiologic 
research 
Abstract 
Introduction 
...................................................................................................................... 63 
...................................................................................................................... 64 
...................................................................................................................... 65 
The Nationwide Inpatient Sample-Healthcare Cost and Utilization Project 
(NIS-HCUP) ...................................................................................................................... 67 
Veterans Affairs Medical Database ............................................................................................ 72 
The Health Improvement Network (THIN) Database ........................................................... 85 
The Norwegian Medical Databases ............................................................................................ 95 
Conclusion 
Tables 
References 
..................................................................................................................... 104 
..................................................................................................................... 106 
...................................................................................................................... 132 
ix 
List of Tables 
Chapter I 
Table 1.1 Demographic and clinical characteristics' among patients with 
hepatotoxicity (cases) and patients with myocardial infarction (controls) in Veterans 
Affairs database between Jan 2002- Jan 2009 ............................................................ 20 
Table 1.2 The result of multivariable model showing the risk of hepatotoxicity 
associated with fluoroquinolones (the crude and adjusted odd ratios of study 
outcomes) ................................................................................................................ 21 
Table 1.3 Risk estimates for hepatotoxicity among users of different 
fluoroquino lones ...................................................................................................... 22 
Chapter II 
Table 11.1 List ofantibacterial agents including in this study .................................. 50 
Table 11.2 Demographic and clinical characteristics among patients with acute 
pancreatitis (cases) and patients with myocardial infarction (controls) in the Veterans 
Affair database (Jan 2002-Dec 2008) ........................................................................ 51 
Table 11.3 The results of multivariable model showing the risk of acute pancreatitis 
associated with antibacterial agents used. . .......... ·: .................................................... 52 
Table 11.4 Estimate of the risk of acute pancreatitis among users of antibacterial 
agents in a population of veterans ............................................................................. 53 
Chapter III 
Table 111.1 Essential elements available in nationwide inpatient sample ............... 106 
Table 111.2 Areas and topics that can be answered through using nationwide inpatient 
sample database ...................................................................................................... 107 
Table 111.3 Examples of research questions that can be answered by nationwide 
inpatient sample ..................................................................................................... 108 
x 
Table 111.4 Primary users of nationwide inpatient sample data ............................... 109 
Table 111.5 Advantages and limitations of the nationwide inpatient 
sample database ..................................................................................................... 110 
Table 111.6 Data sources within Veterans Affairs database .................................... 111 
Table 111.7 The four major datasets in the Medical SAS® Inpatient Datasets and their 
definition ............................... ................................................................................. 114 
Table 111.8 Description of the National Data Extracts datasets .............................. 115 
Table 111.9 Examples of variables in the Pharmacy National Data Extract .......... 117 
Table 111.10 Sources of the laboratory and laboratory results National 
Data Extracts .......................................................................................................... 118 
Table 111.11 Examples of numeric value for non-numeric laboratory test results ... 119 
Table 111.12 Examples of Laboratory Tests those are available in 
Laboratory datasets .............................................................................. .................. 120 
Table 111.13 Advantages and limitations of the VA databases ................................ 121 
Table 111.14 Some variables in the THIN database and their original sources ....... 122 
Table 111.15 Examples of READ codes in the THIN database ............................... 123 
Table 111.16 Examples of British National Formulary (BNF) drug codes in the THIN 
database ................................................................................................................. 124 
Table 111.17 Advantages and limitations of the THIN database .............................. 125 
Table 111.18 Examples of databases available in Norway ....................................... 126 
Table 111.19 Resources for Norwegian Health Information System 
(''Norhealth") .......................................................................................................... 129 
Table 111.20 Aims of the Norwegian Prescription Database (NorPD) .................... 130 
Table 111.21 Variables available at Norwegian Prescription Database (NorPD) ..... 131 
Xl 
CHAPTER I 
Estimating the Risk of Hepatotoxicity Associated with Fluoroquinolone Use: 
A Case-Control Study Using the National Veterans Affairs Database 
This manuscript will be submitted to the Journal of the American Medical Association 
(JAMA) 
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Abstract 
Context: Health care agencies across the world are closely monitoring reports of 
hepatotoxicity linked with fluoroquinolone use. Medications and herbal remedies 
currently account for fifty percent of acute liver failure in the United States and liver 
toxicity is one of the most common reasons for drug removal by the FDA. The 
incidence of hepatotoxicity due to fluoroquinolone use is currently unknown. 
Objective: To assess the risk of hepatotoxicity in patients using fluoroquinolones 
compared to patients who did not use fluoroquinolones among patients admitted to 
Veterans Affairs facilities nationally. 
Design, setting and patient: Matched case control design was used to evaluate a 
national cohort of patients admitted to all Veterans Affair facilities between January 
15\ 2002 and December 31 5\ 2008. Patients diagnosed with hepatotoxicity as primary 
diagnosis served as cases and patients diagnosed with myocardial infarction served as 
the control group. Conditional logistic regression was utilized to compute odds ratios 
and the 95% confidence interyal (CI). Multivariable models were built to adjust and 
control for the potential clinical conditions or covariates that might influence 
hepatotoxicity risk. A stepwise forward entry method (non-computer generated) was 
used to build the final model. 
Main Outcome Measure: The risk of hepatotoxicity associated with fluoroquinolone 
use. 
Results: A total 7,862 patients in the hepatotoxicity-case group and 45,512 patients in 
control group were entered in the final analysis. The mean age of the cases was 58 
2 
years and the majority of the patients were males (96%) and were white (59%), 
followed by black race (18%) and hispanic (4%). After adjusting for potential 
confounders, tluoroquinolone use was significantly associated with increased risk of 
developing hepatotoxicity, odds ratio (OR) was 1.196 (95% Confidence Interval [CI], 
1.039-1.3 75). Further, ciprofloxacin was significantly associated with risk of 
hepatotoxicity, OR, 1.294 (95% CI 1.051-1.58). 
Conclusion: The use of fluoroquinolones was associated with increased risk of 
hepatotoxicity among a national cohort of veterans. 
3 
Background 
Hepatotoxicity, defined as an injury to the liver cells is commonly associated 
with a decrease in liver function. 1 The liver's metabolism and connection with the 
gastro-intestinal tract increases susceptibility to injury from drugs and other ingested 
substances. Hepatotoxicity can range from a mild reaction, which can be resolved by 
discontinuation of the causative agents to a serious fatal reaction. 2 Medications, herbs, 
chemicals and infectious pathogens are the most common causes of hepatotoxicity.3-7 
Although the incidence of drug induced- hepatotoxicity is considered rare -1 in 10,000 
to 1 in 100,000- it is usually clinically significant. 8 
Fifty percent of acute liver failure cases are caused by medications and 5% of 
all hospital admissions are caused by drug-related hepatotoxicity.9 Currently, 
hepatotoxicity is the leading cause of acute liver failure in the United States (US). 
Acute Liver Failure (ALF) due to medications is usually a fatal reaction and only 20% 
of patients will respond to therapy and survive.2 Liver damage due to drugs has 
different features: hepatocellular, cholestatic or a.mixture ofboth. 10-12 There is no 
specific treatment for drug-induced hepatotoxicity in most cases; supportive care and 
withdrawal of causative agent are the only treatment options available. More than 900 
drugs can cause hepatotoxicity. 13 As a cost ofliver toxicity, the average cost of treating 
a patient with acute liver failure using 2001 and 2006 data is estimated at is $146,972 
to $252, 113. 14,15 
Fluoroquinolones are antimicrobial agents that possess a broad spectrum of 
activity against gram-negative and gram-positive organisms. These drugs are widely 
4 
used to treat nosocomial and community acquired infections. 16 Fluoroquinolones are 
"b d d" . 17 one of the most prescn e me 1cat1ons. 
Antimicrobial agents, including fluoroquinolones are the most common cause 
of non-acetaminophen induced hepatotoxicity. 18 Antimicrobial induced hepatotoxicity 
usually is an idiosyncratic reaction, dose independent and unrelated to intended 
pharmacological effect. 18' 19 In the past decade, liver toxicity has been one of the most 
common reasons for drug removal from the U.S. market by the FDA such as 
troglitazone (Rezulin®). 18 
In the United Kingdom (UK), the Medicines and Healthcare products 
Regulatory Agency (MHRA) restricted the indication of moxifloxacin for use only 
when other antibiotics failed to treat acute bacterial sinusitis, acute exacerbation of 
chronic bronchitis or community acquired pneumonia due to the risk of hepatotoxicity 
associated with moxifloxacin. 20 
Increases in the reports ofhepatotoxicity associated with the usage of 
fluoroquino lones are a crucial issue in clinical practice, since fluoroquino lones are 
commonly prescribed because of their broad spectrum of coverage. At the same time 
liver toxicity is a serious issue and 50% of cases are related to medication and not 
related to any underlying diseases. However, in the case reports, the association 
between fluoroquinolones and hepatotoxicity is unclear.21 -24 A well designed 
epidemiological study is necessary to assess the possible increased risk of 
hepatotoxicity associated with fluoroquinolones usage. Therefore, the purpose of this 
5 
study was to conduct a real-world safety study to assess the association between 
fluoroquinolones use and risk ofhepatotoxicity. 
6 
Methods 
Data source 
In United States, the Veterans Affairs (VA) medical database is considered 
from the largest medical database with information for more than 7.9 million veterans. 
2s-27 These data include detailed information on all medical and pharmacy information 
for each patient. All patient data are stored in electronic form. 28'29 Additionally, 
Veteran Health Administration (VHA) runs and operates over 164 hospital and 800 
clinics with more than 180,000 medical personnel. All data are maintained on three 
levels: the local level, the VA Integrated Services Networks (VISN) level, and the 
national level. 30 Every patient treated in any VA hospital or other VA facilities has 
his/her information collected and stored in the National Patient Care Database 
(NPCD), the source data for the VHA medical SAS datasets. Similar to many other 
medical databases, VHA uses the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM ) to code all diseases, procedures, and 
surgeries in the VA datasets. In addition, the Current Procedure Terminology (CPT) 
code system is used to code some procedures in the medical SAS outpatient datasets. 
31 The Diseases coding in the VA database h~s been validated and determined to be of 
high quality. 30,32 
Study design 
A matched case-control study was utilized using a national cohort of patients 
in the VA databases (hospital and pharmacy data) which contain preexisting data to 
examine the association between fluoroquinolone use and development of 
7 
hepatotoxicity. Scrambled Social Security numbers were used to guarantee the privacy 
of the patients. The study was approved by the Institutional Review Board (IRB) of 
the y A research committee and the research office at the University of Rhode Island. 
Cases and controls 
Our patient cohorts were taken from the national VA database in Austin 
(Austin Automation Center; AAC) between January 1st, 2002 and December 31st, 
2008. All patients from the study population diagnosed with hepatotoxicity as primary 
diagnosis were defined as our case patients. Only the first diagnosis for hepatotoxicity 
was considered in the instance of patients who have multiple episodes during the study 
period. Hepatotoxicity term included "hepatotoxicity, acute necrosis of the liver, liver 
toxicity and toxic hepatitis". Hepatotoxicity cases were identified using ICD-9-CM 
codes: hepatic necrosis (570) and toxic hepatitis (573.3). 6'33-35 For each case patient 
we randomly selected up to six controls from the population of patients who were 
diagnosed as primary diagnosis with myocardial infarction (ICD-9-CM 410.00-
410.92). We have chosen myocardial infarction because it has the same 
hepatotoxicity characteristics ·which are acute and serious outcome. For both cases 
and controls, patients with secondary diagnoses for infectious diseases are allowed to 
be included in our study. Controls were match to cases based on month ofadmission. 
We excluded individuals who meet one of the following criteria: liver 
cirrhosis, liver cancer, any type of viral hepatitis, alcoholic hepatotoxicity, 
acetaminophen induce-hepatotoxicity, human immunodeficiency virus/acquired 
immunocompromised deficiency diseases HIV I AIDS, liver abscess and Wilson's 
8 
disease. Also, we excluded patients who were hospitalized during the 180 days prior to 
the admission date. 
Exposure definition 
Definition of drug exposure was as patient received a prescription for 
ciprofloxacin, levofloxacin, or moxifloxacin six months prior to the admission date. 
Medications were identified using drug description variables along with intermediate 
product number (IPNUM) variable. Only outpatients' medications were included in 
the study and most of fluoroquinolones used were oral medications. 
Covariates 
Covariates that were controlled in the logistic regression model include age, 
gender, race, alcohol status ( ICD-9 codes (305.0, 303.0, VI 1.3, V79.1), alcohol 
dependency treatment (BEDSECN=725) and alcohol-related DRGs (DRG=433)), 
smoking status, illicit drug use, comorbidities (history of diabetes, renal diseases , 
hypotension, heart failure, gall bladder disease), medications' prescription data for our 
cases and controls included: tetracyclines, macrolides, amoxicillin, 
amoxicillin/clavulanic acid, isoniazid , rifampicin, pyrazinamide, ethambutol, 
antifungal medications, thiazolidinediones, metformin, Proton Pump Inhibitors (PPis) 
and phenytoin. These medications were selected because they are known to cause 
hepatotoxicity. 1 
9 
Data Analyses 
The primary analysis of the study was to examine the association between the 
development of hepatotoxicity and exposure to fluoroquinolone use. Demographic and 
clinical categorical data was analyzed using X2 test or Fisher's exact test while 
continuous variables were analyzed using a student's t-test or Mann Whitney test. 
Conditional logistic regression was used to compute odds ratio and their 95% 
confidence interval (CI) . Bivariate analyses were initially used for the selection of 
potential clinical covariates for inclusion in the multivariable model. Based on the 
findings of the bivariate analyses, a multivariable model was built to control for the 
potentially confounding variables. Covariates with differences of I 0% between the 
cases and controls were included in the multivariable model. A forward entry method 
(non-computer generated) was used to build the final model, at each step, a covariate 
was added, and ifthe estimated coefficient (B) of fluoroquinolone exposure changes 
by> I 0%, this covariate was kept in the final model. Potential effect modifiers were 
examined by adding specific interaction terms to the conditional logistic regression 
models. At each step, an interaction term was added to the model and the interaction 
will be significant if the estimated coefficient (B) of fluoroquinolone exposure changes 
by> I 0%. Presence of collinearity was assessed by Variation Inflation Factor (VIF) 
using value of 2.5 as cut off 36 All the confounders or covariates were assessed at 
baseline. Subgroup analysis was conducted to study the association between each 
drug ( ciprofloxacin, levofloxacin and moxifloxacin) and their risk of hepatotoxicity. 
All statistical tests were conducted with a two-tailed alpha of 0.05 using SAS® 
version 9 .1.3 (SAS® Institute, Inc, Cary, NC). 
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Results 
There were 21,404 case patients identified with hepatotoxicity. We excluded 
patients with liver cancer (n=l,033), patients with liver cirrhosis and hepatotoxicity 
due to alcohol (n=9,543), patients with HIV/AIDS and Wilson's disease (n=349), 
patients with viral hepatitis (n=l,302), patients with liver abcess (n=48), patients with 
acetaminophen induced hepatotoxicity (n=l 83) and any patient admitted in the last 6 
months prior to the admission date (n=l,084). 7,862 patients were included in the final 
analysis as case group. The majority of our study population was male (96%) and the 
mean age was 58 years for cases and 64 for controls. Approximately, 60% ofcases 
were of white race followed by 17% black. In comparison to the cases, in the control 
group, 64% of patients were white and 11 % black (Table I. I);. In both cases and 
controls, approximately 20% of race is missing which is acceptable if we consider the 
fact that most of administrative databases did not include race. The cases tend to use 
alcohol and illicit drug more than controls while control tend to smoke tobacco more 
than cases. 
Patients in control group had a higher prevalence of diabetes mellitus (33%) in 
comparison to patients in case group (22%) while prevalence of renal disease was 
more in cases (13%) than controls (6%). Other comorbidities were almost the same 
between the cases and controls. 
Medication consumptions were similar between the patients in case group 
compared to the patients in control group with few exceptions. The percentage of 
patients using hypoglycemic agents ''thiazolidinedione and metformin" was more in 
11 
controls (3%, 10%, respectively) compared to cases (1.5, 4.5%, respectively). On the 
other hand, phenytoin was used more in cases (0.80%) compared to controls (0.5%). 
The other medication groups such as tetracyclines, macrolides, amoxicillin/ 
amoxicillin+ clavulnate, anti-tuberculosis medications and antifungal were almost 
similar between cases and controls. 
Odds ratios (OR) and the 95% confidence intervals (CI) were computed from 
the crude and the adjusted conditional logistic regression models. There was a 
statistically significant association between fluoroquino lones use and developing 
hepatotoxicity after adjusting for all potential confounders, the adjusted OR was 1.196 
(95% CI: 1.039-1.3 75) (Table 1.2). Secondary analysis was done to estimate the risk of 
hepatotoxicity with drugs of interests ( ciprofloxacin, levofloxacin and moxifloxacin) 
compared to non users. Ciprofloxacin was statistically significant associated with 
hepatotoxicity OR 1.294 (95% CI 1.051-1.586) (Table 1.3). Further, levofloxacin and 
moxifloxacin were associated with hepatotoxicity as indicated by an OR of 1.164 
(95% CI 0.941-1.439) and OR of 0.98 (95% CI 0.67-1.416) respectively, but these 
associations were not statistically significant. There was no collinearity between the 
variables in our model. 
12 
Discussion 
To our knowledge, this is the first study to examine the association between 
fluoroquinolone antibiotic use and the risk of developing hepatotoxicity. This study 
utilized an extremely large database. 11 Our population was mainly white and male as 
expected since most of the patients were veterans. Patients with hepatotoxicity in our 
study were younger than the controls. This is consistent with many case reports and 
studies that assess the association between hepatotoxicity and medications. 2,23,37,38 
Hepatotoxicity can develop at any age. 2 Based on the results of our study, we found 
that patients with hepatotoxicity are 1.196 times more likely to have been exposed to 
fluoroquinolones than control group. Our results indicate that fluoroquinolones use is 
associated with risk of developing hepatotoxicity. Furthermore, the results showed 
that ciprofloxacin is significantly associated with risk of developing hepatotoxicity 
while levofloxacin and moxifloxacin were not statistically significant associated with 
hepatoto xic ity. 
Gatifloxacin was not included in the study ·because it is no longer actively 
marketed after the 2006. Gatifloxacin had a "Black Box" warning regarding increased 
dysglycemias in diabetic patients before the company stopped manufacturing the 
drug.39 
These observed associations between fluoroquinolones are biological 
plausible. Ciprofloxacin and moxifloxacin are partially metabolized by the liver while 
levofloxacin is largely execreted unchanged by the kidneys. 40-42 Liver enzymes 
elevation occurred in 2-3% of patients with fluoroquinolones. Alanine 
13 
aminotransferase, aspartate aminotransferase, and alkaline phosphatase are the most 
. h fl . 1 43 44 h h reported elevated enzymes wit uoroqumo ones use. ' In umans, t e 
intrahepatic concentrations of fluoroquinolones have been found to be eight times as 
their concentration in the serum. 45 Increasing the concentration of fluoroquinolones in 
the liver might lead to hepatic injury. However, the liver toxicity usually occurred 
when the concentration is 20 times intrahepatically compared to serum concentration. 
45 Therefore, this may be the reason why ciprofloxacin is associated with 
hepatotoxicity and levofloxacin was not. However, moxifloxacin was not associated 
with hepatotoxicity while it is metabolized by liver; this may be because of the small 
number of patients using moxifloxacin. A possible explanation is that, until, 2006, 
ciprofloxacin and gatifloxacin were the fluoroquinolones of choice within the VA 
facilities. Ciprofloxacin was the least expensive drug since it was available as generic. 
46
•
47 Although, there was a new restriction in using moxifloxacin in UK, a recent 
European review assessed the risk of moxifloxacin safety compared to other 
fluoroquinolones. Researchers conclude that hepatotoxicity with moxifloxacin was not 
different than other fluoroquinolones. 48 In addition to the metabolism effect 
mechanism, some literature suggested that fluoroquinolones hepatotoxicity is a 
idiosyncratic drug reaction "immune-mediated" manifested by eosinophilia. 49 This 
mechanism could be the suggested mechanism in the case of medication that is mainly 
eliminated by renal routes such as levofloxacin. 
Although, there is no study to assess the association between fluoroquinolones 
use and risk of hepatotoxicity, SB Meropol et al, compared the incidence rate of 
hepatotoxicity with using three different medications which are ciprofloxacin , 
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amoxicillin and doxycycline. 50 They compared the incidence of hepatotoxicity with 
these medications in three different databases. Overall, the incidence rate of 
hepatotoxicity was more with ciprofloxacin compared to amoxicillin and doxycyline 
(20.6, 1.4, O per 100,000 person day, respectively). The results of this study were 
consistent with our study results. Many case reports questioned the risk of 
hepatotoxicity with fluoroquinolone drugs including, ciprofloxacin, moxifloxacin, and 
levofloxacin. 23'24'38'51 Contreras et al, describe a 32 year old male who was diagnosed 
with septic arthritis in his ankle. He started ciprofloxacin ( 500 mg q 12h) and 
subsequently, the patient developed jaundice, his liver enzymes goes up (AST: 1, 782 
U/L (normally< 35) and ALT:2, 144 U/L (normally< 40). The patient was suspected 
to have ciprofloxacin induce liver failure and admitted to intensive care unit (ICU). 
The patient started to improve and his liver enzymes return to the normal after 6 weeks 
of discontinuing ciprofloxacin. 52 Schwalm and Lee describe a 73 year old male who 
developed acute hepatitis after using levofloxacin 250 mg orally per day. He was 
started on levofloxacin for cellulitis and shortly after initiation oflevofloxacin, his 
liver enzymes increased (AST: 1392 U/L and ALT: 857 U/L). Levofloxacin was 
stopped and within 1 week, the enzymes returned to near normal levels 53 .The time of 
hepatotoxicity in these reports varied between 5 and 35 days. 
Our results indicate that Veterans of Asian race were not at greater risk of 
developing hepatotoxicity compared to black and Hispanic veterans. This result is 
consistent with the fact that Asian patients tend to have faster metabolism compared to 
other races. 54 While, the Native American patients have the highest risk compared to 
other races, this is may be due to different reasons such; Native Americans are using 
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many herbs as treatment and as nutritional supplement and these herbs could have an 
h 1. 55 effect on t e 1ver. 
Patients with myocardial infarction were chosen as the control group because 
they are believed to have many similar characteristics to those with hepatotoxicity, 
including acute onset and serious outcome. In a case control study, having an 
appropriate control group is challenging. 56 Other controls such as those with renal 
diseases cannot be used because there is an association between fluoroquinolones 
medication use and the development of renal diseases.57'58 Additionally, patients with 
injury are not a suitable group because those patients usually have severe 
comorbidities and may be older. 59 One quarter of veterans who served at Iraq and 
Afghanistan are reported to have head and neck injury type, just one type of the many 
.bl . . . 60-62 poss1 e mJunes. 
In our study, we controlled for covariates (social behavior, health conditions 
and medications) that might influence hepatotoxicity. Further, we controlled for the 
possible interactions (2-way and 3-way) to minimize the role of effect modifiers. 
Observational studies, especially those that assess the effects of medications, 
should evaluate the potential of confounding by indication, when seriously ill patients 
being more likely to receive fluoroquinolone medications and more likely to develop 
the outcome. To assess this, first we excluded any patient who has been admitted in 
the hospital to avoid including any very ill patient. Additionally, we were able to 
exclude many major risk factor for hepatotoxicity such as viral hepatitis and liver 
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abscess and finally we controlled for most of relevant comorbidities in our regression 
model. 
The recognized association between fluoroquino lones and hepatotoxicity is not 
new. Trovafloxacin was the first drug from fluoroquinolone medications that 
associated with hepatotoxicity.63 Trovafloxacin is available with special restrictions 
for use only in patients with life-threatening or limb infections because of serious liver 
toxicity including hepatitis, liver failure that resulted in liver transplantation and death. 
64
,
65 In 1999, trovfloxacin was removed from European market because of liver 
• • 66 tox1c1ty. 
Our study has several strengths; we utilized a large database with sufficient 
power to assess the association between fluoroquinolones use and risk of developing 
hepatotoxicity. Moreover, this database allowed us to include patients that may not be 
in other databases, such as those of Native American race and users of illicit drugs. 
We were able to control for many major potential confounders such as liver cancer, 
liver cirrhosis and other risk factors. 
However, our study has several limitations. Since we are using an 
administrative database, there is potentially a problem with coding and missing data, 
especially for behavioral variables such as alcohol abuse and tobacco smoking. In the 
VA database, there are specific variables for alcohol abuse and tobacco use but these 
variables usually are missing at least in the case of our study. Instead, we used ICD-9-
CM codes to detect patients who are smoking tobacco, who have history of smoking 
and patients who are abuse alcoho I. We believe that there may be a an underestimation 
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of the prevalence of these behaviors. Additionally, illicit drug use is determined by 
patients (self identified), not by using analytical test to test these substances in the 
blood. Using this method could underestimate illicit drug use and we speculate that 
not all patients will identify if they use illicit drugs or not. The validity of the ICD-9-
CM code as an indicator for hepatotoxicity is not known. In general, the validity of 
different ICD-9 codes varies. 67'68 However, it is unlikely that hepatotoxicity is 
ignored as a diagnosis. Another limitation of using administrative database is that we 
can't determine whether patients receiving fluoroquinolones actually took their 
medications and adhered to their medication regimen .. The majority of our population 
in the study are veterans males, therefore we may not generalize our results to women 
and non-veteran patients. 
Finally, as with other observational studies, residual confounding cannot be 
completely excluded. 
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Conclusion 
In conclusion, it was found in a large national cohort study that fluoroquinolones use 
is significantly associated with the risk of developing hepatotoxicity compared to non-
use. Furthermore, ciprofloxacin was statistically significant associated with the risk of 
hepatotoxicity compared to non-users. At present, it is believed that clinicians should 
be aware of this potential issue when they prescribe fluoroquinolones in patients who 
are at risk of developing hepatotoxicity. Thus, further research is needed to confirm 
these findings and to better understand the underlying mechanism. 
19 
Table 1.1: Demographic and clinical characteristics' among patients with 
hepatotoxicity (cases) and patients with myocardial infarction (controls) in 
Veterans Affairs database between Jan 2002- Dec 2008. 
Cases Controls P value 
N=7,862 (%) N=45,512 (%) 
Age, mean (SD) 58.4 (12.7) 63.8 (11.0) <0.01 
Sex (%male) 
Race 
White 
Black 
Asian 
Hispanic 
Native American 
Unknown 
Alcohol abuse* 
Smoking* 
Never 
Current 
Past 
Illicit drug use 
Comorbidities 
Diabetes Mellitus 
Hypotension 
Gall bladder disease 
Renal Diseases 
Heart failure 
Prescription medications§ 
Tetracyclines 
Macro Ii des 
Amoxicillin±cal vulante 
Anti-TB 
Anti fungal 
Thiazolidinediones 
Metformin 
Statins 
Proton pump inhibitors 
Phenytoin 
*Based on ICD-9-CM 
96.30% 
4,621 (58.9%) 
1,401 (17.8%) 
37 (0.47%) 
329 (4.2%) 
52 (0.7%) 
1,422 ( 18%) 
493 ( 6.3%) 
6,946 (88.4%) 
805 (10.2%) 
112 ( 1.4%) 
144 ( 1.8%) 
1,787 (22.7%) 
219 ( 2.8%) 
292 ( 3.7%) 
1,02~ ( 13%) 
871 (11.1 %) 
81 ( 1%) 
212 (2.7%) 
169 (2.15%) 
10 (0.13%) 
25 (0.32%) 
125 (1.5%) 
359 (4.5%) 
717 (9.2%) 
858 (10.9%) 
60 (0.8%) 
98.00% 
29,227 (64.2%) 
4,990 (10.9%) 
227 (0.49%) 
1,264 ( 2.9%) 
122 ( 0.3%) 
9,685 (21.3%) 
280 ( 0.6%) 
38,562 (84.7%) 
5,504 (12.9%) 
1,453 ( 3.2%) 
160 (0.35%) 
15, 104 (33%) 
1, 137 (2.5%) 
407 (0.9%) 
2,743 ( 6%) 
5,207 (11.4%) 
535 (1.2%) 
1,231 (2.7%) 
1,082 (2.4%) 
32 (0.07%) 
87 (0.2%) 
1,418 ( 3%) 
4,566 (10%) 
10,469 (23%) 
6,493 (14.3%) 
217 (0.48%) 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
0.13 
<0.01 
<0.01 
0.35 
0.26 
1.00 
0.21 
0.09 
0.02 
<0.01 
<0.01 
<0.01 
<0.01 
0.01 
§Medications known to cause hepatotoxicity 
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Table 1.2: The result of multivariable model showing the risk of hepatotoxicity 
associated with fluoroquinolones (the crude and adjusted odd ratios of study 
outcomes). 
Variable 
Fluroquino lones 
Age 
Gender¥ 
Race§ 
Black 
Hispanic 
Asian 
Native American 
Unknown 
Alco ho 1 abuse 
Smoking$ 
Current smoker 
Ex smoker 
Diabetes mellitus 
Renal diseases 
Gall bladder diseases 
Metformin 
Stat in 
Antifungal 
PPI 
Crude Odds Ratio 
(95%CI) 
1.125 (0.98-1.287) 
0.958 (0.956-0.961) 
1.934 ( 1.688-2.216) 
1.534 ( 1.430-1.646) 
1.673 (1.469-1.904) 
1.100 (0. 767-1.577) 
2.140 (1.514-3.025) 
0.948 (0.886-1.016) 
n 
8.363 (7.168-9. 757) 
0.642 (0.590-0.698) 
0.451 (0.3 70-0.550) 
0.627 (0.592-0.664) 
2.992 (2. 759-3 .246) 
4.740 ( 4.040-5.562) 
0.622 (0.550-0.704) 
0.372 (0.343-0.404) 
1.539 (0.970-2.444) 
0.779 (0.721-0.843) 
*Adjusted for all potential confounders in the table 
¥ The reference group is male gender 
§The reference group is white race 
$Compared to people who never smoke using ICD-9-CM 
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Adjusted Odds Ratio 
(95%CI)* 
1.196 (1.039-1.375) 
0.954 (0.951-0.957) 
1.509 (1.299-1. 753) 
1.4 73 ( 1.369-1.570) 
1.686 (1.471-1.932) 
1.225 (0.845-1. 775) 
2.320 (1.605-3.355) 
0.94 7 (0.885-1.014) 
7.770 (6.629-9.108) 
0.637 (0.585-0.693) 
0.511 (0.414-0.629) 
0.674 (0.632-0. 719) 
3.151 (2.894-3.431) 
4.709 (3.994-5.553) 
0.644 (0.569-0.728) 
0.420 (0.385-0.460) 
1.666 (1.033-2.687) 
0.845 (0.779-0.917) 
Table I.3: Risk estimates for hepatotoxicity among users of different 
fluoroquinolones. 
Drug Cases (n=7,862) Control (n=45,512) Adjusted Odds 
Ratio (95%CI) 
Ciprofloxacin * 124 651 1.29 (1.05-1.58) 
Levofloxacin§ 112 696 1.16 (0.94-1.44) 
Moxiflo xacin t 36 256 0.98 (0.67-1.41) 
*Multivariable model adjusted for age, gender, race, smoking, alcohol abuse, diabetes 
mellitus, renal diseases, metformin use and proton pump inhibitors (PPis) use. 
§Multivariable model adjusted for age, gender, race, alcohol abuse, diabetes mellitus, 
renal disease, gall bladder diseases metformin use and PPis use. 
t Multivariable model adjusted for age, gender, race, alcohol abuse, diabetes mellitus, 
renal diseases and proton pump inhibitors (PP Is) use 
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CHAPTER II 
Antibacterial use and risk of acute pancreatitis: A Case-Control Study Using the 
National Veterans Affairs Database 
This manuscript will be submitted to the Clinical Infectious Diseases (CID) journal 
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Abstract 
Background: Acute pancreatitis is most commonly seen among persons who have 
gall bladder diseases or abuse alcohol. Medications, including antibacterial agents 
have also been reported to cause acute pancreatitis. This requires the Food and Drug 
Administration to focus on the risk of acute pancreatitis with these medication classes. 
Although there are many case reports discussing the risk of acute pancreatitis with 
antibacterial agents, no epidemiological studies have assessed this risk in the United 
States. 
Methods: A matched case control study was conducted among a national sample of 
patients admitted to all Veterans Affairs facilities between January 1, 2002 and June 1, 
2009 to estimate the risk of acute pancreatitis after use of antibacterial agents. A 
patient case was defined as patient diagnosed with acute pancreatitis and the control 
was defined as a patient diagnosed with myocardial infarction. Conditional logistic 
regression was used to compute odds ratios and the 95% confidence interval (CI). 
Multivariable models were built to adjust and contiol for the potential clinical 
conditions or covariates that might influence acute pancreatitis risk. A stepwise 
forward entry method (non-computer generated) was used to develop the final model. 
Results: A total of 10,202 patients with acute pancreatitis and 48, 111 patients with 
myocardial infarction were identified and entered into the analysis. The mean age for 
cases was 55.6 and the mean age for controls was 64.4, and the majority of the study 
sample were males (96.5% ). After adjusting for all potential confounders, antibacterial 
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agents use was significantly associated with increased risk of developing acute 
pancreatitis,. The adjusted odds ratio (AOR) was 1.29 (95% CI 1.18 -1.41). 
Conclusion: Among a national cohort of veterans, acute pancreatitis development was 
associated with antibacterial agent use. 
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Background and Clinical Significance 
Acute pancreatitis is an inflammatory disease that affects the pancreas. It 
usually affects the pancreatic tissues and in some cases, the inflammation involves the 
surrounding tissues. I The amount of inflammation will vary in severity from mild to 
severe, to life threatening. Most cases are mild, resolve within days and may only 
require a short hospital stay. Severe cases may require hospitalized for days and 
sometimes for months due to organ dysfunction. In addition to variety in severity, 
acute pancreatitis can occur as a single attack or it can also be recurrent. Acute 
pancreatitis is associated with 15-35% mortality rate and the incidence of acute 
pancreatitis has increased worldwide.2'3 In the United States, it is estimated that about 
210,000 patients are admitted to the hospital annually for the disease.2 One study 
estimated that an average thirty-nine day hospital stay for acute pancreatitis costs 
approximately $100,000 .4 
There are several causes of acute pancreatitis. Gallbladder disease and chronic 
alcohol consumption are the major causes of acute pancreatitis. Also, hyperlipidemia 
(hypertriglyceridemia, ~ 1000 mg/di), inter-abdominal surgical procedures, trauma 
from endoscopic retrograde cholangiopancreat_ography (ERCP), ischemia, chronic 
hypercalcemia, abdominal trauma, infections, autoimmune, hereditary causes, 
pancreatic tumor, and medications may increase one's risk for developing acute 
pancreatitis.5-I 4 . In addition, 25% of the pancreatitis cases occur with unknown 
etiology. Is Acute pancreatitis has no specific treatment and requires only supportive 
care to prevent complications. I6-18 Acute pancreatitis is a serious disease due to the 
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difficulty in diagnosis, limited therapeutic approaches, and poor prognosis with severe 
cases. 
Medication use is one of the main causes of acute pancreatitis with an 
incidence of 0.1-2%. 19 However, this number may not be accurate because 
pancreatitis is often misdiagnosed, undiagnosed, and underreported 19• Most 
medications associated with acute pancreatitis are based on case reports and few 
epidemiological studies. Over forty drugs are known to cause acute pancreatitis, they 
include; angiotensin converting enzyme inhibitors, estrogen, diuretics, exenatide, and 
antipsychotic are some example of drugs that can induce acute pancreatitis. 15,20-23 
Some antimicrobial agents have been associated with acute pancreatitis such as 
erythromycin, tetracyclines, metronidazole, ertapenem, isoniazide, rifampin and 
ampicillin.24-28 Most of the medication risk observed are based on case reports, and 
there are no known mechanisms to describe how these medications cause acute 
pancreatitis. Direct toxic or hypersensitivity reaction and pancreatic duct constriction 
are some suggested mechanisms. 
The concern over medication, specifically antibacterial agents, causing acute 
pancreatitis is important because of the popularity of these agents. Antibacterial 
agents are used in clinical practice in both community and hospital settings. There is 
therefore a need to understand and determine these potential medical problems risks of 
acute pancreatitis associated with antibacterial medications.23'29 
There are currently a series of epidemiological studies that are assessing the 
risk of acute pancreatitis with different groups of medication (e.g. statins, ACEis, 
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d. d. h · k ·11 · . is 23 30 diuretics). These stu 1es pre 1ct t ens w1 contmue to mcrease. ' ' There are few 
studies that assessed the risk of acute pancreatitis, particularly with antibacterial 
agents. One study assessed diseases and medications as risk factors of acute 
pancreatitis. 7 another study investigated the risk of acute pancreatitis with use of 
metronidazole.31 The aim of the study is to assess and evaluate the risk of acute 
pancreatitis with use of antibacterial drugs among a national cohort of patients 
admitted to Veterans Affairs (VA) facilities. 
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Methods 
Study patients. All patients in VA facilities who were diagnosed with acute 
pancreatitis in the period between January 1, 2002 and June 1, 2009 were selected in 
this retrospective case-control design. Acute pancreatitis cases were identified using 
codes from the International Statistical Classification of Diseases and Related Health 
Problems, 9th revision (ICD-9-CM). The ICD-9-CM code for acute pancreatitis is 
577.00. The study was approved by the Institutional Review Board (IRB) at the 
Providence VA and the research office at the University of Rhode Island. 
Data sources. The Veterans Health Administration (VHA) administrative 
database was utilized to perform this study. There is data for more than 7.9 million 
veterans maintained and stored in the Veterans Affairs (VA) medical database, making 
it one from the largest medical database in the United States. 32-34 . Additionally The 
VA healthcare system includes more than 180,000 medical personnel operating over 
164 hospitals, 800 clinics, and 135 nursing homes as of2001. Patients' data in the VA 
database is retained on three levels: the local level, the VA Integrated Ser_vices 
Networks (VISN) level, and the national level. 35 The VA database contains all 
medical and pharmacy information for each individual in electronic form. 36'37 All 
diseases, procedures, and surgeries in the VA database datasets are coded using the 
ICD-9-CM , although some procedures in Medical SAS outpatient datasets are coded 
using Current Procedure Terminology (CPT). 38 Many studies have validated the 
disease coding in the VA database. 35,39 All data required for the study were available 
except for weight and height. Weight and height figures were obtained from corporate 
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data warehouse (CDW), the national repository containing data from many clinical 
and administrative systems within the VHA. 
Case definition and selection of control subjects. Our case patients were 
defined as patients who were diagnosed with acute pancreatitis as their primary 
diagnosis using ICD-9-CM codes. Only the first diagnosis for acute pancreatitis was 
included in patients who had multiple episodes during the study period. For each case 
patient, six controls were randomly selected from the population of patients who were 
diagnosed with myocardial infarction (ICD-9-CM 410.00-410.92) as their primary 
diagnosis and who do not have acute pancreatitis. Controls were matched to cases 
based upon month of admission. We selected myocardial infarction as the control 
group because these patients present with both acute symptoms and serious outcomes, 
similar to acute pancreatitis. For both cases and controls, any patient with infectious 
disease as secondary diagnosis was allowed to be included in the study. The date of 
admission was defined as the index date. 
Patients with peptic ulcer, hemorrhagic ulcer, gastritis, patients who had 
ERCP, abdominal trauma, any type of cancer (including pancreatic cancer), human 
immunodeficiency virus/acquired immunodefi~iency syndrome "HIV I AIDS", chronic 
pancreatitis, bacteremia, alcohol related diseases, gall bladder diseases, and 
esophagitis were excluded from the study. Also, patients who were hospitalized during 
the 180 days prior to the admission date were excluded. 
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Potential covariates. The covariates that were included in the logistic regression 
model included age, gender, race, alcohol use (the database indicator entries for 
alcohol dependency treatment (BEDSECN=725), alcohol-related DRGs (DRG=433), 
ICD-9 codes (305.0, 303.0, VI 1.3, V79.l)), co-morbidities, diabetes, alcohol related 
diseases (liver and mental), and inflammatory bowel disease (IBD).40 All prescription 
medication data for cases and controls, including drugs that are associated with acute 
pancreatitis such as hydrochlorothiazide, prednisone, valproic acid, non-steroidal anti-
inflammatory drugs (NSAIDs), and azathiopurine were also controlled in the logistic 
. d 1 24,40-45 
regression mo e . 
Exposure definition. Drug exposure was defined as having received a prescription 
of any antimicrobial drug within ninety days prior to the index date. Antimicrobial 
medications included the following groups: penicillins, cephalosporins, macrolides, 
fluoroquinolones, tetracyclines, clindamycin, metronidazole, nitrofurantoin, 
isoniazide, rifampin, pyrazinamide, ethambutol and trimethoprime/sulfamethoxazole 
(Table II. I). Drug description variables and the inte~mediate product number 
(IPNUM) variable were used to identified patient Medications. Only outpatient oral 
medications were included in the study. 
Statistical Analyses. The main analysis of the current study was to investigate the 
association between the risk of acute pancreatitis and exposure to antibacterial 
medications. A chi-square test or Fisher exact tests were used to analyze the 
categorical data while a student's t-test or Mann Whitney test were used to analyze the 
Continuous variables for both demographic and clinical data. Odds ratio and their 95% 
confidence interval (CI) were derived from the conditional logistic regression. 
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Initially, the potential clinical covariates that would be entered the multivariable 
model were selected based on bivariate analyses. Covariates with differences of 10% 
between the cases and controls were included in the multivariable model. Then, the 
final model was built using stepwise forward entry method (non-computer generated). 
At each time, a covariate was added, and ifthe estimated coefficient (B) of 
antimicrobial exposure changed by more than 10%, this covariate was kept in the final 
model. Furthermore, two-way and three-way interactions were assessed. At each step, 
an interaction term was added to the model, and if the estimated coefficient (B) of 
antimicrobial exposure changed by more than 10%, the interaction term was kept in 
the model. Multicollinearity was assessed using variance inflation factor (VIF). A 
cutoff of2.5 for VIF was used to indicate the presence of multicollinearity. All 
statistical tests were conducted with a two-tailed alpha of 0.05. All analyses were 
conducted using SAS® version 9 .1.3 (SAS® Institute, Inc, Cary, NC). 
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Results 
Between January 1, 2002 and June 1, 2009, a total of23,899 patients were 
identified with a primary diagnosis of acute pancreatitis. Inclusion and exclusion 
criterion for the study were applied to these patients. Among these cases, patients with 
of any type of cancer, including pancreatic cancer, (n=899), chronic pancreatitis (n= 
2,861), HIV or AIDS (n=369), bacteremia (n=578), ERCP (n=295), abdominal injury 
(n=9), alcohol related diseases (n=l,842), .gall bladder or biliary diseases (n=3,528), 
peptic/hemorrhagic ulcer or gastritis (n=376) and esophagitis (n=2,222) were 
excluded. In addition, patients who were admitted to the hospital for any medical 
conditions in the previous 180 days prior to the index date (n=718) were excluded 
from the study. After application of the exclusion criteria, 10,202 patients were 
eligible for the analyses. 
The Distribution of demographic and clinical characteristics of the cases 
(patients with acute pancreatitis) and the controls (patients with acute myocardial 
infarction) can be found in Table 11.2. Patients in the case group were younger (mean 
age 55.6) than the patients in the control group (mean age 64.4). The majority of our 
population was male. In general, our sample's racial breakdown was mainly white 
non-Hispanic (58%), followed by black (18.5%). The control group had a higher 
percentage of white non-Hispanic (63.9%) compared to the case group (52.3%). The 
case group had a higher percentage of black patients (24.3%) compared to the control 
group (12.6%). Also, there were more native Americans in the case group (0.50%) 
compared to the control group (0.30%). There was no difference among Asian and 
Hispanic races. 
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The case group differed from the control group in alcohol abuse, 
hypertriglyceridemia, hypercalcemia, and IBD, while there was no difference in other 
covariates such as diabetes mellitus and use of comparable prescription medications 
( Table II.2). 
Fluoroquinolones antibiotics were the most used antibiotics among case group 
patients and control group patients (2.8% and 2.9 respectively), followed by penicillin 
(2.7% and 2.3%, respectively). Nitrofurantoin (0.03 and 0.08, respectively) and anti-
tuberculoses medication (0.04 and 0.05, respectively) were the lowest utilized 
antibiotics by the study population. Use of sulfamethoxazole/trimethoprim was equal 
among case group patients and control group patients (0.9%). 
Odds ratios (OR) and the 95% confidence intervals (CI) were computed from 
the adjusted conditional logistic regression model (Table II.3 & Table II.4). After 
controlling for all of the potential confounders in the multivariable model, there was a 
statistically significant association between antibacterial use and developing acute 
pancreatitis. The adjusted odds ratio (AOR) was 1.29 (95% CI 1.18 -1.41 ), suggesting 
that patients with acute pancreatitis are 1.29 times more likely to have been exposed to 
antibacterial agents than control group. 
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Discussion 
The current study utilized a matched case control study design using the 
national Veterans' Affairs database to investigate the association between the use of 
antibacterial drugs and acute pancreatitis development. To current knowledge, this is 
the first epidemiological study to assess this association for all oral antibacterial agents 
as one group in the United States. 
There is a known risk with metronidazole use and the risk of acute pancreatitis. 
Previous investigations found an association with metronidazole use within thirty days 
prior to index date (AOR was 3 .0, 95% CI 1.4-6.6). 31 Furthermore, they found that 
patients who used metronidazole with proton pump inhibitors to treat peptic ulcers due 
to helicobacter pylori and/or using amoxicillin, macrolides, or tetracycline within 
thirty days prior to index date were at risk of developing acute pancreatitis (AOR was 
8.3, 95% CI 2.6-26.4). 31 However, it is important to note that the increased risk in 
patients with peptic ulcers could be due other confounding factors. 
Investigators in Swede~ used a population case control study to investigate 
disease and medication risk factors for acute pancreatitis. The risk of using systemic 
antibacterial agents was evaluated in addition to several other medication classes. 
After adjusting all the potential confounders, the AOR was 1.9, 95% CI 1.1-3.2, 
indicating that systemic antibacterial agents were associated with acute pancreatitis 
development. 7 
Numerous case reports have linked acute pancreatitis with several antibacterial 
agents. Penicillins, fluoroquinolones, macrolides, tetracyclines, metronidazole, and 
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sulfamethoxazole-trimethoprim are some of the antibacterial agents that have case 
. h . . 28 46-56 h . . f h 
reports associating them wit acute pancreat1tls. ' T e maJonty o t ese case 
reports found that patients with acute pancreatitis induced by antibacterial agents were 
middle aged. This data is consistent with our results. In this study, the patients with 
acute pancreatitis were younger than the control group. Newer antibacterial agents 
f . . 27 57 also have generated case reports o acute pancreatitis. ' 
Another report described a case of acute pancreatitis that resulted from using 
tigecycline, a compound related to tetracyclines. 57 The patient was a thirty five year 
old male, who had undergone surgery to remove tissue that was infected with 
Enterobacter cloacae. He was initially given tigecycline, imipenem and amikacin. 
After thirteen days of treatment, he developed upper abdominal pain, and his lipase 
level was elevated. He was subsequently diagnosed with acute pancreatitis. 
Tigecycline and amikacin were stopped; the patient's lipase level then started to 
decrease and he was no longer experiencing any abdominal pain. After five months, 
his lab tests returned to baseline. 
The incidence of drug induced acute pancreatitis is between 0.1-2%.19 
Although the exact mechanism of antibacterial induced acute pancreatitis is still not 
known, several mechanisms were suggested for different antibacterial groups. The 
mechanisms for tetracyclines to be associated with acute pancreatitis were suggested 
as: (1) accumulation of toxic metabolite, (2) hypertriglycerdemia induced by 
tetracyclines, and (3) increased concentration of tetracyclines in the biliary duct. It is 
theorized that the formation and accumulation of a toxic tetracycline metabolite is 
responsible for causing acute pancreatitis, although no metabolite has been identified 
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yet. 58 Furthermore, tetracyclines inhibit protein synthesis, which could lead to a build 
up of defective protein within the hepatocyte and inhibit triglyceride release to the 
liver. This process leads to increased triglyceride levels causing acute pancreatitis. 59 
The other possible mechanism is that the high concentration of tetracyclines in the bile 
is the major reason for tetracyclines induced acute pancreatitis. 57 Minocycline 
concentration in bile was found to be ten times the concurrent serum concentration. 59 
Also, the concentration of doxycycline and tetracycline in the bile reached up to eight 
times and 1 O times the serum concentration, respectively. 6° Further, tigecycline 
biliary elimination rate is 500 times the plasma rate, which could be a major reason for 
. . 59 
acute pancreatlt1s. 
An rational for acute pancreatitis and macrolides use has been postulated. It is 
suggested that macrolides cause acute pancreatitis through their prokinetic property. 
They stimulate contraction of gastrointestinal tract, resulting in spasms and increased 
pressure of the sphincter of Oddi and bile reflux. 7'49'61 -63 Some medications diffuse 
directly to the pancreas, leading to acute pancreatitis by direct toxic effect through the 
release of free radicals like in the case of metronidazole. 19'28'64'65 Immune mediated 
reaction, hypersensitivity reaction, and toxic effect are suggested mechanisms of drug 
induced acute pancreatitis in several antibiotics such as sulfonamides, anti tuberculosis 
medications, and nitrofurantoin. 7' 19,66,67 Generally, middle-aged patients are at greater 
risk of developing acute pancreatitis than elderly patients and black patients at greater 
risk than white patients, which are both consistent with this study' s results. 68 
Antibacterial agents are considered an integral part in the therapeutic plan for 
acute pancreatitis to prevent the complications of acute pancreatitis such as 
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bacteremia. 1 However, using antibacterial agents in acute pancreatitis still remains 
controversial. 69 Using antibacterial agents in patients with acute pancreatitis is based 
upon results from a randomized clinical trial that found administration of imipenem 
reduced infectious complications. 70 However, a recent randomized clinical trial that 
compared ciprofloxacin plus metronidazole to placebo and found there is no difference 
in outcomes between the two groups.71 Therefore, routine use of prophylactic 
antibiotics in acute pancreatitis is not recommended until the patient develops an 
infection. This study's results also support these recommendations since it was found 
that antibacterial agents were associated with acute pancreatitis. Thus, unnecessarily 
giving the patient with acute pancreatitis prophylactic antibacterial agents to prevent 
infections should be avoided since these medications were associated with acute 
pancreatitis development. 
Several indicators were used to find patients with alcohol use among the cases 
and controls. These indicators included ICD-9 codes, alcohol dependency treatment 
indicators, and alcohol-related DRGs. This variable in the model was determined 
using the previous indicators. The Department of Veterans Affairs (VA) requires an 
annual alcohol screening for any VA patient.72 In 2000, the screening rate was 85%, 
which is considering a high rate.73 To continue this screening program of VA patients, 
the Veterans Health Administration (VHA) implemented an evidence-based alcohol 
screening program. A study done in 2006 found that the screening rate of alcohol 
misuse was 93%.74 Additionally, the Computerized Patient Record System (CPRS) at 
the VA has a reminder for the clinician to perform an AUDIT- consumption (AUDIT-
C) questionnaire for alcohol misuse.74 These programs were established for the 
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purpose of screening as well as providing counseling to patients with alcohol misuse. 
Based on these programs, it was determined that virtually all VA patients 
werescreened for alcohol use. 
In any observational study, the potential of confounding by indication should 
be evaluated. Confounding by indication is when patients with severe diseases and 
comorbidities were more likely to received antibacterial agents than those with 
moderate diseases. In this study, patients with major risk factors (e.g. patients with 
gall bladder diseases and alcohol related disease) and those who had been admitted in 
the hospital during the last six months prior to the index date were excluded from the 
study. Additionally, the remaining variables were controlled in the regression model. 
This study has several strengths. The use of a very large database provides data 
for a large sample size. This allowed all exclusion and inclusion criteria that have been 
identified to be applied. Additionally, many potential confounders such as 
hypertriglycerdemia, alcohol abuse, and other confounders were controlled. 
While this study has several strengths, it also has potential limitations. As with 
all administrative databases, the pharmacy data describes the dispensed antibacterial 
agents, but it is not known if the patients were actually administered their medications. 
Also, the validity of acute pancreatitis diagnosis in the VA databases was not 
evaluated and assessed in an epidemiological study. The diagnosis of acute 
pancreatitis may be underestimated and not classified in mild cases. 75 additionally, 
incideince of drug induced acute pancreatitis is not accurate because it is often 
misdiagnosed, undiagnosed and underreporting. 19 Furthermore, as with most of 
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administrative databases, missing data and missing codes are always potential 
problems. In this study, initial plans included incorporating BMI in the analysis. 
Weight and height were used to calculate BMI, but up to 48% of the height and weight 
values were missing. Therefore, it was decided not to include BMI in this study. 
Additionally, the majority of the population in the study are male veterans, therefore 
the results may not be generalized to women and non-veteran patients. Finally, as 
with other observational studies, residual confounding cannot be completely excluded. 
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Conclusion 
In conclusion, it was found that antibacterial medications were significantly 
associated with increased risk of acute pancreatitis among a large national sample of 
veterans. In addition, further studies are required to confirm this conclusion and to 
understand the underlying mechanism of this association. Further research is also 
required to investigate the role of individual antibacterial agent is in the development 
of acute pancreatitis. 
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Table 11.1: List of antibacterial agents including in this study. 
Antibacterial group Drug name 
Penicillin Penicillin VK 
Amo xic illin 
Cephalosporin 
Macrolide 
Fluoroquinolone 
Tetracycline 
Lincosamides 
Anti-tuberculosis 
Nitroimidazole 
Miscellaneous 
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Amoxic ii lin/ c la vu lnate 
Cloxacillin 
Cephalexin 
Cephradine 
Cefaclor 
Cefuroxime 
Cefprozil 
Cefixime 
Erythromycin 
Azithromycin 
Erythromycin 
Ciprofloxacin 
Levofloxacin 
Moxifloxacin 
Tetracycline 
Oxytetracycline 
Doxycycline 
Minocycline 
Clindamycin 
Isoniazide 
Rifampin 
Pyrazinamide 
Ethambutol 
Metronidazo le 
Trimethorpim/Sulfamethoxazole 
Nitro furanto in 
Table 11.2: Demographic and clinical characteristics among patients with acute 
ancreatitis (cases) and patients with myocardial infarction (controls) in the ~eterans Affair database (Jan 2002-June 2009). 
Age, mean (SD) 
Gender (male%) 
Race 
White 
Black 
Asian 
Hispanic 
Native American 
Unknown 
Alco ho 1 abuse* 
Co morbidities 
Diabetes Mellitus 
Hypertriglyceridemia 
Hypercalcemia 
Inflammatory Bowel 
Diseases (IBD) 
Prescription 
Medications§ 
Cases (N= I 0,202) 
55.6 (12.3) 
95.4% 
5,336 (52.3%) 
2,479 (24.3%) 
50 (0.49%) 
335 (3.3%) 
51 (0.50%) 
1,951 (19%) 
3,502 (34.3%) 
3,545 (34.8%) 
970 (9.5%) 
99 (0.97%) 
97 (0.95%) 
Controls (N=48, 111) 
64.4 (11.7) 
97.9% 
30,723 (63.9%) 
6,052 (12.6%) 
218 (0.45%) 
1,645 (3.4%) 
149 (0.30%) 
9,351 (19.3%) 
2,247 (4.7%) 
17,656 (36.7%) 
1,033 (2.2%) 
112 (0.23%) 
137 (0.28%) 
p 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
Prednisone 161 (1.6%) 952 (1.9%) 0.01 
Valproicacid 18(0.18%) 46(0.10%) 0.03 
Azathioprine 13 (0.13%) 38 (0.08%) 0.13 
SSRI 791 (7.8%) . 3,044 (6.3%) <0.01 
NSAID's 781 (7.66%) 3,693 (7.68%) 0.94 
Hydrochlorothiazide 783 ·(7.67%) 3,649 (7.58%) 0.75 
Antifungal 19 (0.19%) 48 (0.10%) 0.02 
*Based on ICD-9-CM, alcohol-related DRGs and alcohol dependency indicator 
§Medications known to cause acute pancreatitis 
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Tables II.3: The results of multivariable model showing the risk of acute 
pancreatitis associated with antibacterial agents used. 
Variable Crude Odds Ratio Adjusted OR (95% CI)* 
(95%CI) 
Antibacterial agents 1.18 (1.09-1.29) 1.29 (1.18-1.41) 
Age 0.94 (0.93-0.94) 0.96 (0.95-0.97) 
Gender$ 2.14 ( 1.87-2.4 7) 2.10 ( 1.83-2.41) 
Race§ 
Black 1.83 (1.71-1.95) 1.58 (1.47-1.70) 
Hispanic 1.17 (1.02-1.35) 1.16 (0.99-1.35) 
Asian 1.48 (1.04-2.12) 1.62 (1.13-2.33) 
Native American 1.55 (1.08-2.24) 1.33 (0.89-1.98) 
Unknown 1.18 ( 1.11-1.27) 1.18 ( 1.11-1.27) 
Alcohol abuse 7.32 (6.83-7.86) 7.10 (6.61-7.61) 
SSRI 1.18 ( 1.08-1.30) 1.30 (1.18-1.44) 
* Adjusted for all potential confounders in the table 
$ The reference group is male gender 
§ The reference group is white race 
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Tables II.4 Estimate of the risk of acute pancreatitis among users of antibacterial 
agents in a population of veterans. 
Cases (n=l0,202) 
(%) 
1007 (9.87%) 
Controls (n=48,lll) 
(%) 
4485 (9.32%) Antibacterial 
agents 
*Adjusted for all potential confounders in the table 11.3 
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Adjusted OR 
(95%CI)* 
1.29 (1.18- 1.41) 
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CHAPTER III 
Review the healthcare databases in United States and European countries that 
are commonly utilized in conducting epidemiologic research 
This manuscript will be submitted to the Pharmacoepidemiology and Drug Safety 
(PDS) journal 
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Abstract 
Medical databases play a major role in conducting pharmacoepidemiological 
studies. They are used to perform descriptive and observational studies. Having an 
ideal database is challenging and not easy to find, especially in countries lacking a 
universal healthcare system. Countries with a social healthcare system have the ideal 
environment to have an ideal medical database. There are many medical databases in 
the U.S as well as Europe and other countries worldwide. Each database has its own 
structure with unique variables included in that database. Also, each database has its 
own strengths and limitations, giving each one the ability to answer different research 
questions. In this review, four databases will be investigated. Two databases from the 
U.S., the NIS-HCUP database and the VA database, and two databases from Europe, 
the THIN database and the Norwegian databases are included in this review. In 
addition to providing detailed information on each database, the purpose of this review 
is to explain the differences between the U.S databases and Europe databases and the 
benefit of having a social healthcare system in the competence and validity of these 
databases. 
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Introduction 
Computerized healthcare database or medical databases contain a variety of 
information that can be used for descriptive and observational studies. These medical 
databases provide sufficient information to answer research questions related to 
health, including diseases, drug therapies, and beneficial and adverse effects to drug 
therapies. 1 The strengths and weaknesses of each database vary and are limited to the 
data collected and the quality of the input. 
Healthcare databases are divided into medical record databases and 
administrative databases. Various healthcare databases are available in United States 
(U.S.) as well as in other countries.2 The Veterans Affairs (VA) database, Group 
Health Cooperative of Puget Sound, Medicaid, and Kaiser Permanente Medical Care 
Programs are some examples of healthcare databases in the U.S. In Europe, there is 
generally a universal healthcare system, and large collective databases making for are 
an ideal database to study where complete healthcare information is needed. 
The ideal healthcare database would include inpatient care, outpatient care, 
emergency care, mental health care, laboratory tests, radiological tests, prescribed and 
over the counter (OTC) medications, and alternative therapies.2'3 In addition to 
medical information, the availability of economic data (direct and indirect medical 
costs) increases the capability of the database, especially when 
pharmacoepidemiologic and pharmacoeconomic studies are being performed. 
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With a wide variety of healthcare databases available to the researcher, many 
research questions can be answered by comparing the research question to the 
different components of the various databases. 
We conducted a comprehensive review of four different globally available 
databases. We will describe each database, identify the advantages and disadvantages, 
and the type of research questions that can be answered using the database. Included 
in this review are two databases from the United States (The Nationwide Inpatient 
Sample-Healthcare Cost and Utilization Project (NIS-HCUP), and the Veterans' 
Affairs (VA) Medical Database), the Health Improvement Network (THIN) from the 
United Kingdom, and the Norwegian medical databases. A lack of publically 
available resources on the Canadian and Japanese medical databases limited our 
attempt to critique them in this review. 
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The Nationwide Inpatient Sample-Healthcare Cost and Utilization 
Project (NIS-HCUP) 
The largest all-payer inpatient care database in the United States is said to be 
the Nationwide Inpatient Sample (NIS) medical database. It was created under the 
Healthcare Cost and Utilization Project (HCUP), which is a large family of healthcare 
databases.4'5 The Kids' Inpatient Database, the State Inpatient Databases, the State 
Ambulatory Surgery Databases and the State Emergency Department Databases are 
also members in HCUP databases. The HCUP is federally supported and sponsored 
by the Agency for Healthcare Research and Quality (AHRQ).6 The NIS database 
released its first dataset in 1988, which at that time, included information from eight 
states. State participation increased considerably and in 2007, AHRQ collected data 
from 1,044 hospitals in forty states.4 This Nationwide Inpatient Sample represents 
about a 20% stratified sample of all patients admitted to community hospitals in the 
U.S annually and in 2007, 90% of all hospital discharges in the United States were 
included in the sampling frame ofNIS. To establish a sample that represents the 
hospitalization in United States, ·the hospitals selected in NIS were stratified based on 
five characteristics: U.S. geographic region, bed size, teaching status, rural or urban 
location, and ownership. 5'7'8 Community hospitals are defined by the American 
Hospital Association (AHA) as all public, non-federal, short-term hospitals where the 
average length of stay is less than 30 days. These hospitals have identifiers that 
connect to the AHA annual survey database and county identifiers that permit linkages 
to the Area Resource File. 5 This database has been used by many researchers to 
identify and analyze different national healthcare trends, including, healthcare 
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utilization, charges, quality, access, and outcomes. 9-11 Since 1988 all datasets are 
publicly available to conduct research projects and to analyze information regarding 
different types of diseases and medical conditions as well as other aspects of health. 
One of the main advantages ofNIS is the ability to run an analysis of trends over 
time.4 In 1988, the estimated number of discharges was slightly over 35 million 
observations in comparison to 39 million discharges in 2005. This database continues 
to grow. NIS contains a significant amount of data, including information that cannot 
be studied in other medical databases, specifically, it contains information on rare 
diseases such as autoimmune hepatitis; uncommon treatments such as organ 
transplantation; and special groups of patients, such as the uninsured patients.4'12 
Essential elements of NIS 
The information included in NIS consists of patient hospitalization admission 
and discharge information. NIS has more than 100 clinical and nonclinical data 
components for each hospital admission. These elements include primary and 
secondary diagnoses, primary and secondary procedures, admission source, discharge 
destination, payment source, and hospital characteristics (hospital size and teaching 
status) (Tables III.I). 4'8 Descriptive data regarding patient demographics, include 
age, gender, race, and the median income for each area (via zip code) is also included. 
In addition, other elements have been added, such as all patient refined 
diagnosis related groups (APR-DRGs), all payer Severity-Adjusted Diagnosis related 
groups (APS-DRGs), disease staging, and AHRQ co-morbidity indicators.4 The 
typical discharge abstract includes all clinical and resource use information, which are 
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all protected to safeguard the privacy of the individual patient, physician, and hospital. 
The confidentiality of individuals' information is achieved by using two procedures: 
(I) no patient identifiers are included in the discharge abstracts or other parts of the 
database, and (2) researchers or users of the database agree, through data use 
agreement, to use the data for research and statistical purposes without any attempt to 
identify individuals. 4'6' 13 Nevertheless, NIS excludes any data elements that could 
directly or indirectly lead to the identification of individuals. The identity of some 
institutions can be released when the data resources of these institutions are available 
to the public or there is an agreement to release the information. 4,l 3,1 4 
Using NIS 
Like most U.S medical databases, all diagnoses in NIS database are recorded 
using administrative data. The NIS uses the International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) and up to 15 diagnoses are 
recoded.8' 15 To enable researchers to perform a study that spans multiple years, NIS 
created NIS- trends supplemental files (NIS-Trends) . .Jt is recommended to include 
only years after 1993 to perform ~tudy with trend analysis. 12 Since NIS is a uniform, 
multiple-year and multi-state database, it could be used to explore different topics such 
as quality of care, medical treatment effectiveness, or healthcare cost (Table III.2). 
Furthermore, it is useful for answering research questions related to patient outcomes, 
cost of hospital care provided to specific populations, cost of treating different types of 
diseases, and other salient healthcare questions (Table IIl.3). 4' 16 
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The diversity of the NIS database and the extensive data available attracts 
many profit and non-profit organizations' researchers to utilize this data source. State 
and federal government agencies, healthcare consultants, hospitals, and healthcare 
systems are the main users of NIS (Table III.4 ). 4 
Access to NIS database 
NIS datasets can be accessed through the HCUP central distributer 
(http://wwvv.hcup-us.ahrq.gov/nisovervicw . .i.fill ). New data are released each year. 
This can be downloaded to a desktop computer with CD-ROM reader, and can be run 
using statistical software packages such as Statistical Analysis System (SAS)®, 
Statistical Package for the Social Sciences (SPSS)® and Stata®. To obtain the datasets, 
a NIS Data Use Agreement must be signed to guarantee the privacy and security of 
individual information. In addition, a dataset charge is assessed, which is considerable 
inexpensive in comparison to the real value of the datasets. The dataset for year 2006 
may cost $200, which includes a set of two CD-RO Ms and accompanying 
documentation. HCUP supports NIS' s users with "HCUP User Support" to answer 
questions through a toll free nu~ber and via email. 4 
Advantages and limitation of the NIS database 
NIS is the largest all-payer inpatient database in the United States5'6 It is 
unique because it has data documentation containing many variables for a large 
number of patients. It started in 1988, making it a useful database to perform analysis 
of trends over time. It also covers thirty eight states, and it samples 90% of all hospital 
discharges in the United States, allowing for appropriate representative of the US 
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population. Other reasons that make NIS a valuable database include its ability to 
study rare diseases due to the large number of documented patients and to perform 
studies in different areas such as healthcare cost, epidemiology of diseases, access to 
care, quality of care, and health outcomes with the information regarding different 
sources of insurance (e.g. Medicaid, Medicare, private insurance companies) and 
uninsured patients. On the other hand, NIS has some limitations. One major limitation 
is the lack of pharmacy data therefore, performing studies related to medications is not 
possible. 17 In addition, data outside the hospital system (i.e. outpatient physician 
office) is not available. NIS database does not include data on alcoholism and drugs 
abuse and the data on race and ethnicity is incomplete in some states (Table III.5). 5 
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Veterans Affairs Medical Database 
The Veteran Health Administration (VHA) is a part of the United States 
Department of Veterans Affairs (VA). VHA services began in 1777 when the first 
federal hospital was built in Pittsburgh. 18 The hospital originally offered surgical 
services to military personnel. 19 Between 1916 and 1945, the VA hospitals broadened 
their medical expertise and the number of hospitals increased. 19 20 21 After 1980, the 
VA expanded into a powerful health system in the United States by opening and 
operating numerous hospitals, outpatient clinics, medical centers, and long-term health 
care facilities across the country. Currently, the VA operates 163 medical centers, 909 
ambulatory care and community-based outpatient clinics, 232 Veterans Centers, 137 
nursing homes, 108 comprehensive home-care programs, and 4 7 residential 
rehabilitation treatment programs, providing high quality medical, surgical, and 
rehabilitative care. 22'23 
The Veterans Affairs (VA) medical database is considered from the largest 
medical databases in the United States. 24-26 It contains information for more than 
seven million veterans and their dependents. 22'27 The large number of patients in the 
VA medical database makes it a very unique database that can address many research 
questions. 
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v A structure and information center 
The VA database maintains patients' data on three tiers: the local level, the VA 
Integrated Service Networks (VISN) level, and the national level. The local level 
refers to the patient data in the Veterans Health Information Systems and Technology 
Architecture (VistA) system, which is usually one medical facility. The second level is 
VISN level, whereby VHA structured and grouped medical facilities across the 
country are divided into 21 VISN s. VISN s are classified based on their geographical 
area. The VISN database contains data from multiple VistA giving it more data than 
the local level but less data than the national level. For the purpose ofresearch in a 
specific health or medical field, the appropriate choice would be the national level 
database. The national level is a combination all local facilities stored in a central 
location. National data is maintained by The National Data Systems (NDS) Division 
oflnformation Assurance, VHA Office oflnformation. 28 Housed in Austin, Texas, 
the Austin Information Technology Center (AITC) is the central location for the 
national level database, and the V A's centralized computer-processing center. 28,29 
The VA Information Resource Center (VIReC) is responsible for assisting 
researchers on how to use the database and giving full information about the datasets 
in AITC. In addition, VIReC provides detailed information in different areas such as 
requesting access to the datasets, programming tips, and how to connect to the Austin 
mainframe to run analyses. 14,30 All medical variables are described in detail and 
determined in which file these variables are available. 14 
73 
Data structure 
There are different data sources within the VA database that can be utilized by 
researchers to conduct their studies (Table III.6). 31 '32 Each separate data source has 
different types of information that helps to conduct several types of studies (medical 
and non-medical). This review will focus on VA Decision Support System (DSS) 
(production data and National Data Extracts) and the VHA Medical SAS® Datasets 
because they are the most utilized datasets. 31 
The VHA Medical SAS Datasets 
The VHA Medical SAS® Datasets include all of the healthcare utilization 
information for veterans who have been treated in VA hospitals or other treatment 
facilities. These datasets include information on non-veterans such as VA employees 
and research participants. 33 These data are extracted from national patient care 
database (NPCD) and provided in SAS® format for each fiscal year (Oct 1 - Sep 30). 
All VHA Medical SAS® Datasets are stored on an IBM mainframe computer at the 
Austin Information Technology Center and maintained by the VHA Office of 
Information at the same center. Patient information transmitted from the local VistA to 
the Austin Automation Center (AAC), where it is converted to SAS format. 
The VHA Medical SAS® datasets include two major datasets: Medical SAS® 
Inpatient Datasets and Medical SAS® Outpatient Datasets. 33'34 
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Medical SAS® Inpatient Datasets 
The Medical SAS® Inpatient Datasets have four main categories for inpatient 
admissions: acute care, extended care, observation care, and non-VA care. Within 
each type ofcare, there are four datasets: main, bed section, procedure, and surgery. 
All the categories have these four datasets (main section, bed section, procedure 
section and surgery section) except observation care, which has only main, bed section 
and procedure. The definitions of these datasets are illustrated in Table III. 7. t4,33 
The main section dataset includes most of the important inpatient variables, 
such as demographic data, socioeconomic data, and clinical data. It includes one 
principal diagnosis, or the condition causing the patient admission to the hospital and 
up to twelve secondary diagnoses. Other variables included in the datasets are date of 
admission and date of discharge (time, date, month and year), date of death, drug 
related group (DRG), race , ethnicity, source of admission, and VISN number. Bed 
section dataset refers to the patient care that is provided by treating specialty during 
the inpatient stay and does not refer to a physical location of care, it has variables 
related to the bed section, such as admission and discharge date and DRG for bed 
section. It also has one primary diagnosis or the main reason for the full stay in bed 
section, and up to four secondary diagnoses. It has very unique variables not contained 
in other datasets, including a drug abuse indicator and a suicide indicator. The 
procedure dataset contains data for each procedure performed during the inpatient 
stay. It includes up to five procedure codes for the diagnosis, admission, and discharge 
dates and other procedure variables. The surgery datasets contain up to five surgery 
codes for the diagnoses, date of admission and discharge, and other variables related to 
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surgery. A Scrambled Social Security Number (SCRSSN) is used as an Identification 
Number (ID) for each patient to protect patient privacy. All of these datasets can be 
combined using SCRSSN. 35 
Medical SAS® Outpatient Datasets 
The Medical SAS® Outpatient Datasets include patient information that is 
available in the VHA's ambulatory care. This data is collected and stored at the Austin 
Information Technology Center (AITC). This data is transferred from each local 
VistA and organized "electronically" at AITC. This data is updated by AITC every 
two weeks. Medical SAS® Outpatient Datasets include three datasets; visit dataset, 
event dataset, and inpatient encounter datasets. The visit dataset was created in 1980 
and contains information about each day's outpatient care encounter. It contains all 
patient's demographic data and clinic stop codes (up to fifteen codes) for a day's care. 
Any patient who has been seen in any of the VA outpatient clinics has a record. The 
event dataset was created in 1997 and contains information for each ambulatory clinic 
stop by a patient during a day's outpatient care. The event dataset is larger than the 
visit dataset in the number of va~iables and has no limited number of clinic stops. It 
has information regarding patients' demographic data and procedures and surgery 
performed in an outpatient setting. There is one primary diagnosis and nine secondary 
diagnoses. The inpatient encounters dataset includes information about each 
outpatient encounter during an inpatient stay. It is similar to the event dataset, 
although it does have more variables. It is the only dataset among outpatient datasets 
that contains the admission date and discharge date. 30'36 
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Coding system 
All diseases, procedures, and surgeries in the Medical SAS® Inpatient Datasets 
are coded using ICD-9-CM. The ICD-9-CM is also used to code diseases and 
surgeries in Medical SAS® Outpatient Dataset while Current Procedure Terminology 
(CPT) is used to code procedures. Smoking and substance abuse are very important 
issues in any dataset; there are different sources of coding for these variables, using 
ICD-9-CM in Medical inpatient dataset "in main and bed section" to find the patients 
who are smoker or substance abuser. In addition there is a substance abuse indicator in 
bed section. In medical outpatient datasets, these variables can be captured using ICD-
9-CM in Visit dataset while clinic stop coded can be used in both Event and Inpatient 
Encounter datasets. 35-37 
VHA Decision Support System (DSS) 
The VHA Decision Support System (DSS) is a national system using specific 
software to integrate clinical and financial data for both inpatient and outpatient care. 
This software transports the patient data from three main resources: VistA, NPCD, and 
Patient Treatment File (PTF). VHA DSS was created in 1994 and completed in 1999. 
It has three levels of aggregation: VHA DSS Production databases, VHA DSS Report 
summary, and VHA DSS National Data Extracts (NDE). 38 
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VHA DSS Production Databases 
DSS production database contains data regarding costs; clinical information, 
such as resource utilization and patient outcomes; and workload captured over 
different levels (e.g. encounter, day and laboratory results). The software also has 
tools to help the researcher or the team staffs to perform a variety of analyses. The 
researcher can study a pattern of care for inpatient stay, following a cohort of patients 
with a specific outcome over time; study a specific topic related to laboratory results; 
. d f . ·1 h . 37 38 or a multitu e o s1m1 ar researc questions. ' 
VHA DSS Report summary 
DSS report summaries are provided by the VISN Supported Service Center 
(VSSC). These reports are made using National DSS SAS Datasets and can be 
accessed and downloaded through the VA intranet website. Hundreds of reports are 
available in the VA intranet, such as average patient cost, costs by DRGs, and other 
reports. 37 
VHA DSS National Data Extracts (NDE) 
VHA DSS NDE has been created by co-working between the DSS Program 
Office and the VHA VSSC selected database fields. These NDE datasets are created in 
SAS format and each dataset is released in January for the fiscal year that ends on 
September 30th. DSS SAS NDE are stored and housed in AAC (Table III.8). 37'38 
In this review, Pharmacy National Data Extracts, Laboratory National Data 
Extracts, and Laboratory Result National Data Extracts will be discussed in detail. 
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The Radiology National Data Extracts are very similar to the datasets that are included 
in the review; it has the same sources, structure, and some similar variables. 
Pharmacy National Data Extracts 
Pharmacy datasets are often the largest component of the database, forcing 
them to be separated based on VISN. In 2002 and 2003, the pharmacy datasets were 
divided based on group of VISNs (e.g. VISN 1 - 5 Inpatient, VISN 6 - 10 inpatient, 
VISN 11-16, VISN 17-22 and the same arrangement for outpatient files), but starting 
in 2004, these datasets were divided based on each individual VISN combining both 
inpatient and outpatient (e.g. VISN 1, VISN 2 consecutively through VISN 23). These 
datasets include records of every prescription filled by a VA outpatient pharmacy or 
by the Consolidated Mail Outpatient Pharmacy (CMOP), each inpatient unit dose 
order, and every IV solution that is dispensed from a pharmacy. Ward stock 
medications, Bar Code Medication Administration (BCMA) packages, and controlled 
substances are not included in these datasets. 37,39 
Different sources, including the VistA Pharmacy Prescription File, the Unit 
Dose Extract File, and the IV Extract File, are used to collect the medication data. 
DSS files are the source for all information pertaining to costs. Patient demographics 
are collected from patient's file, and encounter information is collected by VistA 
Patient Care Encounter file (PCE). 37 
In addition to pharmacy data, both the direct cost (e.g. drug cost) and the 
indirect cost (e.g. the indirect costs of medical center) are included in the dataset. 
Other datasets inside NDE, including the Outpatient Extract, Inpatient Discharge 
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Extract, and Inpatient Treating Specialty Extract, have some pharmacy cost 
information. This additional information is one of the major strengths of these datasets 
as it is not available in many non-VA databases.40'41 
In the dataset, there is one section for inpatient encounter records and another 
section for outpatient encounter records. The inpatient encounter records contain all 
inpatient pharmacy prescription starting from admission until discharge. The 
outpatient encounter records contain all outpatient pharmacy prescriptions. In these 
datasets, there are more than thirty seven variables that include demographic, 
medication, and cost data. Most of these variables use a code unique for pharmacy 
datasets, such as VA_Class, Intermediate Product Number (IPNUM), INOUT. 
IPNUM variable refers to the DSS product number that is assigned to each drug. 
IPNUM can be used to identify a patient's medications and the drug description 
variable (DRUGDESC). These variables are updated every time for easy use 
(Table III.9). 37'42 
These datasets are very useful to conduct many researches because they have 
all of the important medication information, including the name of the drug. National 
Drug Code (NDC), formulary indicator (formulary Vs non-formulary), fill date 
(service date), quantity dispensed, all cost types, patient SCRSSN, age, gender, 
provider identification number , and provider treating specialty. 37'43 
The DSS Pharmacy NDEs are a major source for researchers to conduct 
research requiring information on medications. They are not the only datasets that 
include medication information, but they are the largest. 
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Other pharmacy resources 
In addition to the DSS Pharmacy National Data Extract, other important 
resources include VISTA system, DSS National Pharmacy Extract "Planned" datasets, 
and the Pharmacy Benefits Management (PBM) group. 41 ,44 
Laboratory National Data Extracts and Laboratory Results National Data 
Extracts 
Laboratory National Data Extracts and laboratory results National Data 
Extracts were created in 2002 and 2000, respectively. As in Pharmacy NDEs, these 
datasets have been divided based on groups ofVISNs until 2003. After 2003, these 
datasets were produced for each individual VISN (e.g. VISNl ... VISN23). 37 
Laboratory ND Es include all laboratory workload data and the cost of these laboratory 
tests. The laboratory tests and laboratory results are entered at the individual level for 
both inpatient and outpatient encounters. 43 
The major source of these extracts is the DSS: DSS records all patient entries 
in the VistA lab package, which are then transported to laboratory and laboratory 
result datasets. Each year, DSS posts more tests in the datasets, and by the 2008 
fiscal year, these datasets included seventy one of the most commonly ordered tests. 
The result of these seventy one laboratory tests are extracted from the laboratory result 
NDEs. 37'43 VistA system is not the only source for laboratory and laboratory results 
datasets. Other sources are used to collect demographic, clinical, and economic 
information. These resources are patient file (#2) , the referral patient file (#67), VistA 
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patient movement file (#405), VistA patient care encounter file, and DSS processes 
43 (Table III.10). 
Both datasets have very useful variables that can be used to obtain data related 
to laboratory tests and laboratory results, including date of admission, date of 
discharge, time collection of the specimen, date of service, and other variables. Each 
dataset has its own unique variables, for instance cost data is only found in laboratory 
datasets. These cost variables include ACT_ COST "actual total cost," LAB_ VD 
"laboratory variable direct costs," LAB_FD "laboratory fixed direct costs," and 
LAB _FI "laboratory fixed indirect costs." Another unique variable is TESTNAME, 
which is used to determine the name of the test. On the other hand, Laboratory results 
datasets have DSSLARNO, which is the test number in the laboratory results dataset, 
and HILO_IND, which is to indicate the abnormality oftest results. These two 
variables are only in laboratory results datasets. Both datasets have the SCRSSN 
variable for each individual patient to help combine these and other datasets. 37,43 ,45 ,46 
The datasets include both inpatient and outpatient laboratory tests and their 
results. All inpatient laboratory tests and the results are placed in each inpatient 
encounter record by DSS. The encounter starts from the date of admission until the 
discharge date. Outpatient laboratory tests and laboratory results that are done in the 
same day are appointed to a single outpatient encounter regardless of how many tests 
are performed. Laboratory tests results are presented in a non-numeric field, such as 
positive or negative, but DSS software does not read non-numeric values. Therefore, 
these non-numeric values need to be translated into a numeric field to be recognized 
by DSS software. This step is performed by the DSS Laboratory Results VistA 
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extract. These translation values (i.e. 0, 1, 2, 3 .... etc) are placed in the DSS and on the 
NDE "laboratory results extracts" (Table III.11 ). 
In 2000, DSS started posting the laboratory results. Laboratory test results 
started with forty tests in 2000 and new tests have been added in each subsequent year. 
There were nine, one, six and three tests added in 2001, 2002, 2003 and 2004 
respectively. In 2008, there were seventy one of the most common tests chosen to be 
in these datasets (Table III.12). 
Access to VA database 
To access the VA database, different procedures are required depending on the 
type of the dataset(s) needed. To access VHA Medical SAS Datasets and VHA 
Decision Support System (DSS), a Time Share Option (TSO) user account is required. 
Also, permission is required to utilize the required datasets. A specific form (VA Form 
9957) is required to identify and access the required dataset(s). These datasets are 
housed and maintained by the Austin Information Technology Center (AITC). 
Advantages and Limitations 
Veterans Affairs medical databases are a unique and comprehensive databases 
(Table III.13). However, the VA databases have some limitations, such as the validity 
of ICD-9 for some diseases. For example, based on a study done in 2009, the ICD-9 
for gout disease is not accurate.47 Another study found that using ICD-9 to identify 
viral hepatitis (type B) is not accurate in the VA database. 48 Nevertheless, many 
diseases have an accurate ICD-9, such as opportunistic infections and serious bacterial 
infections, chronic liver diseases, viral hepatitis (type C), HIV, and many other 
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diseases.48,49 Not all demographic data such as height and weight is available directly 
by using medical SAS® databases or DSS databases. The Corporate Data Warehouse 
(CDW), another medical database, should be used to access these variables. CDW 
requires researchers to submit certain documents if they require access. 
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The Health Improvement Network (THIN) database 
In the United Kingdom (UK), there are more than fourteen databases 
containing clinical and demographical data for patients in the UK. 50 Most of 
European countries, such as the UK, Germany, the Netherlands, and Norway, have a 
national healthcare system. Having a national healthcare system is beneficial for a 
comprehensive and ideal healthcare database. In the UK, the National Health Service 
(NHS) is a government agency that is responsible for health services. One of largest 
health agencies in European countries, the World Health Organization (WHO) also 
considers it to be one of the best agencies. It has over 1.3 million employees, 
including doctors, nurses, and technicians. The entire population is required to be 
registered with one General Practitioner (GP). Information is transferred if patients 
switch to a different GP. To facilitate this information sharing, the UK started to 
compile several databases back in the late 1980s. The General Practice Research 
Database (GPRD) was formed from the old electronic databases in 1987 by Value 
Added Medical Products (VAMP) Health. 50'51 The QPRD contains patients' 
demographic, medical, prescription, and laboratory data. 52 The Health Improvement 
Network (THIN) database was created in November 2002 and includes patients' data 
from 1985 until today. 50'52 THIN is a result of collaboration between the two large 
companies; EPIC and Cegedim. EPIC is a non-profit company that has expertise in 
providing primary care patient data and facilitates access to electronic research data. In 
addition to providing a data source for research, THIN was created with the aim to 
improve the quality and completeness of recording of clinical data in GP practices. It 
was created by Dr. Alan Dean, who is also the creator of GPRD. His experience in 
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accessing the primary care research data has played a major role in the development of 
the THIN database. Cegedim is a European company and parent company ofln 
Practice Systems (INPS), which is responsible for developing and providing the vision 
practice software.53'54 This software is the same software that is used by GPRD. 55 and 
is used by over 95% of the primary care practice and health boards in the UK. 54 
Although the THIN database is a new database, it is considered a good alternative 
resource for medical research since it has informative, valuable, and has complete data 
for each patient. Considering how new this database is, it has a very high possibility 
of becoming one of the premier healthcare databases in the UK. 
THIN Data 
In UK, the general practitioner is considered as gate keeper for the patients as 
they are required to visit their GP if they need medical assistance. There are only a 
few exceptions to this rule. When the patient visits the GP, the GP will assess the 
patient's case and decide to either issue a prescription, refer the patient to a specialist, 
refer them for tests, refer to an emergency room, arrange for hospital admission, or 
offer advice. A patient does not need to go to the GP first if he/she is receiving 
services from an emergency room, a dentist, an optician, or a family planning and 
sexual health clinic. 56'57 At each practice site, the GP has all the information for the 
patient using INPS 's vision software "general practice management software 
package." THIN collects a patient's data from participating GP practices without any 
disruptions to the GP's work. Then, THIN sends all the data on monthly basis to 
EPIC, and EPIC, in turn, sends the datasets to the interested researchers to conduct 
th . 58 
err research. All patient data collected by THIN and sent to EPIC are collected 
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using de-identified information making a patient's identity no longer available in the 
THIN database. C55) All data collection procedures are approved by the an ethics 
committee (Southeast Multi-Centre Research Ethics Committee ; MREC). 
Additionally, all studies that are going to be conducted using the THIN database need 
to be approved by MREC. In the near future, the approval process will be changed, 
whereby the scientific protocol review committee (SPRC ) will replace MREC. Unless 
these studies need to collect additional data or need validation, MREC's approval is 
still required. 53 In April, 2009, the THIN database had data from over 7 million 
patients (approximately 3 million active patients) from over 386 practices. Some of 
these practices are also found in GPRD, creating an overlap between GPRD and THIN 
in some practices. However, the THIN database contains data from practices that have 
never been in GPRD. 55'59 
THIN database contains demographic, medical, and prescription data at the 
patient level. THIN provides a longitudinal record for each patient organized at the 
practice level. Furthermore, the data is arranged in four files, or datasets, and two 
linked files per practice. The main files contain different patient, medical, therapeutic, 
and additional health data (AHD) files, and the two linked files are postcode variable 
indicators (PVI) file and dosage records file. These files were created in 2002 and they 
contain data for some patients as far back as 1985. 53 '58 The patient file contains 
complete demographic data, including the patient unique identifier, age, year of birth, 
gender, death date, registration date with the practice, and date of leaving if the patient 
leaves a specific practice. The medical file contains all health and disease conditions 
and symptoms recorded at the GP office as well as the patient unique identifier. These 
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files include the event date, diagnosis, diagnostic data (e.g. X-ray, CT scan, MRI and 
others), episode type, location of consultation, medical history, and referral data 
(Table III.14). 53 '58'59 If the patient is transferred to secondary care, all the data from 
their secondary care is sent back to the GP and entered into the system. 58 This data 
consists of very detailed information including type of specialty; hospital admission; 
hospital discharge, diagnosis, and medication; outpatient consultation diagnosis; 
. . d t t t t 52'58 investigation; an rea men ou come. 
All health conditions and diseases in THIN databases are coded using the 
READ clinical classification version 2. 60 READ codes are alphanumeric codes that 
define diseases using a hierarchical nosologic system (Table III.15). 61 -65 The code 
terms used in READ are related to the observations (signs and symptoms), diagnoses, 
procedures, and laboratory and radiologic tests. 53 The therapy file includes 
information about prescription data. After the GP enters the prescription data, one 
copy is sent to the pharmacy and one printed copy is given to the patient to take it to 
the pharmacy. 58 Using this procedure creates a medication record for each patient that 
includes all medication prescribed. for the patient since his or her first day of 
registration at the GP office. Medication information in the THIN database includes 
patient unique identifier, product code, British National Code (BNF), date of 
prescription, formulation of the drug, dose strength of the drug, indication for 
treatment, duration of prescription in days, route of administration, prescriber 
identifier, and prescription type (acute or refill). 52'59 Drugs are coded using First 
Databank' s Multilex® coding system and the BNF coding system (Table 111.16). 
58,66,67 
There are three codes for BNF (BNF code 1, BNF code2, BNF code3) each 
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representing different groups of medications. Therefore, some medications that may 
have more than one BNF code. For example, aspirin can be classified as a non-
steroidal anti-inflammatory drug (NSAID) and an anti-platelet. 68 The above 
procedure ensures most medications are well recorded in the THIN database with only 
a few exceptions. Controlled substances, immunizations, and drugs administered 
during home visits are not issued from the computer but are entered into the system at 
a later time. Therefore, there is a chance of under-recording these groups of 
medications. Over the counter (OTC) medications may also be included in the THIN 
database if the OTC drug has been prescribed by the GP. 58,68,69 
Medication that is prescribed outside the GP office by hospital physicians and 
specialist physicians usually is not recorded in the system, excluding it from the THIN 
database. However, if the patient continues to take the medication that he/she started 
taking in the hospital, the drug will be recorded in the database because the patient 
will follow up with the GP. 58 Some of the medications data from outpatient specialty 
care may also be found in the GP summary. 58 
The additional health data (AHD) file contains supplemental information such 
as patient unique identifier, GP consultations, details from other healthcare 
interventions, patient's height and weight, allergies, vaccinations and immunization, 
contraceptive prescriptions, pregnancy, birth details, death details, laboratory tests 
and results, and life style information including smoking and alcoho 1 intake. 53 '59 
Recently, the pathology laboratory has been electronically linked to many practices 
making it easier to record patient tests results and store them in their records. 
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Some of the data in AHD can be found in other files. For example, data on 
smoking and alcoho 1 use can be found in medical records, and contraception data can 
be found in therapy files and in medical files. 68 
In addition to these main files, EPIC creates Postcode Variable Indicators 
(PVI). PVI files provide unidentified postcodes which link the area based on 
socioeconomic, ethnicity, and environmental characteristics to help researchers who 
are planning to conduct a study using THIN to understand the differences between the 
areas to avoid any potential bias or confounders that could affect the study. Under the 
PVI file, there are information related to the degree of deprivation, ethnicity, and the 
degree of pollution (with particulate matter 10 (PMI 0), sulfur dioxide (S02) and 
nitrogen dioxide (N02). Each one of these three variables is matched to the UK 
postcode. The ethnicity is categorized into white, black, mixed, Asian, and 
other. 53,58,59 
Additional information about any patient may be obtained through the 
Additional Information Service (AIS), which includes· information such as death 
certificate, unidentified questionnaires filled out by the patient or by the GP, and a 
specific intervention (e.g. specific diagnostic test to confirm a specific diagnosis). 59 
Validation of THIN database 
Although the THIN database, created in 2002, is considered a new database, 
many studies have been conducted using this database. 70-73 Validity of the information 
in the database needs to be investigated, especially the diagnosis of the diseases. A 
study in 2006 investigated the validity of THIN database through conducting different 
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case control studies to study the association between disease and drug use (e.g. peptic 
ulcer medication and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) use) and 
between diseases (hypertension and stroke). The results of the four studies were 
consistent with the information in the literature. Additionally, in their results, they 
found that the results were identical between the GPRD practices and non-GPRD 
practice. In their conclusion, they stated that the results of the different studies support 
the validity of data within the THIN database. 55 Another study, assessed the quality 
of the THIN database by assessing the quality of the practices that participated in 
THIN. Two hundred thirty six practice sites agreed to participate. They concluded 
that all of these practices demonstrated a high level of completeness ofrecording the 
clinical information in many of the practices. 74 Recently, many studies have been 
done to validate the THIN database and it found that the data in THIN database are 
valid and accurate . 55'75 In addition to these studies, researchers can request EPIC to 
validate the information of their study using the THIN database. 68 
THIN database files structure 
THIN provides the entirety of each file in the American Standard Code for 
Information Interchange (ASCII) format, a standardized fixed width text format, 
making it "user friendly" for researchers. THIN database users can load and import the 
files into different database and statistical software such as Oracle®, Statistical 
Package for the Social Sciences (SPSS®), Structured Query Language (SQL), 
Statistical Analysis Software (SAS®), and Microsoft Access® 53 . All of these files have 
a patient unique identifier (patid) allowing all of the files to be linked together using 
patid. In addition, all files are sorted by patid and by date. 
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Access 
EPIC is responsible for providing access to the THIN database. 53'59 They 
facilitate access to the data in several ways. First, they provide raw datasets to the 
researching organization to perform their own research. They also perform some 
statistical analysis based on the submitted protocol. Furthermore, they help obtain 
additional information from the GP and coordinate with AIS Company. EPIC 
provides the dataset on hard-drives, tapes, and compact discs (CDs). 53,76 Researchers 
from the UK as well as other countries worldwide can access THIN database to 
conduct their research. Any researcher wanting to use the THIN database to conduct a 
study needs to get an ethical approval for their protocol from the UK MERC. 
Advantages and limitations of THIN database 
The THIN database has many advantages for both the health system in the UK 
and for research studies (Table III.17). It helps to improve the quality of clinical data 
recording and, subsequently, will improve the quality of healthcare in the UK. THIN 
offers many training sessions for the users (GP and researchers) to become familiar 
with the database. 77 THIN is a computerized database, allowing for the compilation of 
complete and updated data for each patient. Therefore, any investigator can obtain 
new and additional patient information for a study. It is a population-based database, 
so selection bias will be minimized making epidemiological study more valid. 58 In 
addition, recall and interviewer biases are not a problem since all information that has 
been collected is not based on patient recall. Additionally, in conducting 
epidemiological study, the cases and controls are derived from the same type of 
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population. Therefore, all the criteria inside the database were applied to all patients 
(including cases and controls). Another advantage of the THIN database is that it 
contains longitudinal data allowing studies with long follow up to be conducted easily. 
Another advantage of THIN database is the size of database. It has a large 
number of patients enabling many health conditions, including rare conditions, to be 
studied. The THIN database has been validated through many studies, and these 
studies have found the information inside THIN database to be valid and complete. 
55
,
75 This is one of the important issues for any database. However, additional studies 
are still needed to validate different disease states. 
Finally, researchers have the ability to access the original medical records 
pertaining to the topic being studied. The researcher can request a copy of a patient's 
medical record (non-electronic). There will not be any identification for the patient on 
the medical record, but this service can help the researcher in many aspects such as 
validating the information and getting detailed information about the patient. 68 
However, there are some disadvantages to using the THIN database. As a UK 
population database, THIN database has several limitations: first, it can only be 
generalized to UK population, not other populations. Secondly, the data in the THIN 
database may not be complete enough given the fact that there are a lot of 
communications between the GPs and specialists and hospitals that may not be found 
in the database. Some conditions and symptoms may not be found in the THIN 
database such as headache and cold symptoms, especially if the GP did not prescribe 
any medication for the patient. In addition, information about OTC medications are 
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not available in the databases except if they were prescribed by the GP. Also, 
medications that were prescribed by specialists may not be found in the database. 
Psychiatry medications may also not be found if the patients were treated by 
community mental health teams. As with many databases, obtaining complete race and 
ethnicity information is still a problem with the THIN database. ethnicity information 
is available but incomplete.78 Finally, the THIN database is very costly, and the 
researcher must pay extra for additional services (i.e. accessing non electronic medical 
records). 
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The Norwegian Medical Database 
Norway, a Scandinavian country in Europe, has a population of 4.8 million as 
of 2009. 79 The population has increased by 1. 5 million since 19 5 0. 80 This increase in 
the growth rate was caused by a rising birth rate, prolonged life expectancy, and an 
increased number of immigrants to Norway. Norway is considered to be among the 
highest ranked nation in the number of immigrants. Norway has many strengths in its 
educational and economic systems. 81 More than 57% of the population aged 16 and 
more had completed their secondary school, placing Norway among the most educated 
. Id .d 81 82 countnes wor w1 e. ' 
The healthcare system in Norway is structured on three levels: the national 
level, the regional level, and the local level. The national level is responsible for 
establishing and providing necessary legislation, determining the national health 
policy, and funding the health services. 81 '83 The regional and local levels are 
responsible for providing the health care services through a network of hospitals, 
primary care clinics, psychiatric clinics, pharmacies, outpatient clinics, dental clinics, 
ambulance services, and other health services. 81 Overall, the regional authority is 
responsible for specialist healthcare while the local level is responsible for primary 
health care. The Ministry of Health and Care Services is responsible at the national 
level. Norway has an excellent environment to have a good healthcare system. Its 
national health system grants each citizen the right to health services access regardless 
of their geographic location or economic and social status. 81 This allows each patient 
to go to the primary care or hospital when he/she is sick. Access to healthcare creates 
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data about most people's health status that can be used to build a comprehensive 
database for most of the population in Norway. 
The Royal Norwegian Ministry of Health and Care Services (Helse-og 
omsorgs departementet ) is the superior agency that is responsible for providing the 
healthcare services to the Norway population. There are several agencies that are 
under the ministry of health umbrella that have an important role in the healthcare 
system and medical database development in Norway, such as the Norwegian Institute 
of Public Health, Norwegian Board of Health Supervision, Norwegian Medicines 
Agency and Norwegian Directorate of Health. 81 ,84 
Patient pathway 
Patients who seek medical advice or therapy must visit the general practitioner 
(GP) first . Approximately, 99% of the population is registered with one general 
practitioner. The ministry of health gives the freedom to the patient to choose a GP 
among from a list in their local area. 81 '85 The GP is usually located at the 
municipality' s level and acts as a gatekeeper to further medical care. The GP will take 
one of the following actions: diagnose the patient and give the suitable treatment or 
make a referral if the patient needs to be seen by a specialist physician. The specialist 
physicians are located at the specialized healthcare centers or institutes. The 
specialized healthcare centers include hospitals and specialized medical services such 
as laboratory services, radiology services, and special care for alcoholics and or 
persons with drug addiction. Furthermore, it includes somatic and psychiatry 
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institutes. 81 '84'86 Each regional healthcare authority is responsible for running these 
centers to deliver high quality specialized healthcare to each patient in the region. 81 
Registries and databases 
As mentioned previously, Norway has a good healthcare system to build good 
registries and databases. In Norway, there are different types of databases that focus 
on different areas at different levels (i.e. hospital level and population level). The two 
types of electronic databases at the hospital level are the local electronic level and the 
national electronic level. At the local electronic level, there is an electronic database in 
the hospital that includes all patients' information during the hospitalization. This 
information includes the patient identification number, admission and discharge dates, 
codes for one primary diagnosis and secondary diagnoses, and codes for surgical 
procedures performed at the hospital. 87 The national electronic database, "The 
Norwegian Patient Register," includes patients' information from all hospitals in 
Norway. The Norwegian Patient Register includes an anonymous patient number, 
which contains the number for each year and number for the hospital. It also includes 
one primary diagnosis and two se~ondary diagnoses. 87 '88 More than 90% of the 
primary care physicians and hospitals already use the electronic health record system 
(EHR). This method of electronic documentation has many benefits including building 
the electronic database and reducing the risk of losing important clinical documents. 89 
Other types of specific databases or registries are The Cause of Death Register, 
The Cancer Registry of Norway, The Medical Birth Registry of Norway, The 
Norwegian Surveillance System for Communicable Diseases (MSIS), The 
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Tuberculosis Registry, The Childhood Vaccination Register (SYSV AK) and The 
Norwegian Prescription Database. 9° Furthermore, there are more specialized registries 
like the National Injury Register (NIR) and Database over Occupational Injuries and 
Occupational Diseases (Table III.18). 91 These databases and registries are run by 
different institutes such as The Norwegian Institute of Public Health, Institute of 
Epidemiological Cancer Research Statistics of Norway, and The Association of 
Norwegian Insurance Companies. 90'91 Additionally, there are other discontinued 
databases that have available data and can still be accessed. 91 
Previous databases were used to establish a new monitoring system that 
combined many health indicators that make it a comprehensive database 
(Table III.19). 92 Since the official registries and databases in Norway have the patient 
unique personal identification number, it became a very useful tool to link these 
registries together to make this monitoring health system. Additionally, this method 
assists linking the health information with other information such as education and 
socioeconomic data. It is called Norhealth, or the Norwegian Health Information 
System, and it is used to monitor health related conditions over time. Having a system 
like Norhealth helps to produce a very good health monitoring system and high quality 
research using the variety health indicators from different types of registries. 
Norhealth includes basic elements such as population and socioeconomic factors, risk 
and protective factors, morbidities and diseases, births and abortions, health services 
and treatment, mortality, determinants of health (lifestyle, biological measurement, 
vaccination), and social inequalities in health. As of 2008, there are fifty health 
indicators with over seventy health indicators slated in the future. 92 
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The Norwegian Prescription Database (NorPD) "Reseptregisteret" 
In Norway, their drug database has different transition levels. In 2000, the 
Royal Ministry of Health and Care Services decide to established a national 
prescription registry. The Department of Pharmacoepidemiology was established in 
2002 under Division of Epidemiology at NIPH. 93 The Department of 
Pharmacoepidemiology is responsible for drug consumption in Norway, developing 
and maintaining the anatomical therapeutic chemical (ATC) classification system, 
defining daily doses (DDDs) for international use and to run NorPD. Additionally, the 
World Health Organization (WHO) Collaborating Centre is located at the Department 
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In October 2003, the final regulation on the Norwegian prescription database 
was released to achieve many objectives. The regulation obligates pharmacies in 
Norway to submit all prescription data "electronically" to NIPH on a monthly basis. 95 
The main objective ofNorPD is to collect and process the data on drug utilization for 
both humans and animals. In addition to this main objective, NorPD has several aims 
(Table III.20). 93,96 In January 2004, all pharmacies in Norway started to send data on 
dispensed prescriptions to NIPH. Each year, the Pharmacoepidemiology Department 
at NIPH receives data for over 34 million prescriptions from over 600 pharmacies in 
Norway. Since all pharmacies have a computerized system for entering and dispensing 
the prescribed medications, this helps in transmitting the data to NIPH. From 
NorPD's establishment until 2007, over 150 million records are available for over 4.2 
million patients. 93,97 
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In NorPD, there are several variables for every record for each element in the 
prescription pathway (i.e. patient data; prescriber data, drug data and pharmacy data). 
Some examples of these variables are the patient identification number, patient age 
and gender, prescriber specialty, prescriber profession, number of drug packages 
dispensed, ATC codes and DDDs, date of dispensing, and pharmacy name and license 
number (Table III.21). NorPD has this data for all dispensed prescriptions and over 
the counter (OTC) medications prescribed by a physician. 
Nonvegian databases and pharmacoepidemiological research 
In addition to being important in conducting a pharmacoepidemiological 
research, NorPD is used to produce statistics on medications in Norway such as 
number of medication users; stratification of users by variables such as age, sex, 
county, and other variables; turn over in dosage; and any statistics about the variables 
in NorPD. 96 
NorPD can be used alone and with other databases as well. It can be used alone 
to conduct research related to medications because all variables regarding medications 
are available in NorPD. Also, it can be used alone to conduct 
pharmacoepidemiological research given that some medications can be used as proxy 
for diseases in cases where there is no data about diagnosis. The main advantage in 
Norway is that most of the databases contain the patient's personal identification 
number allowing these databases to be linked together using the patient identification 
b 93 98 . num er. ' NorPD can be lmked to several other databases. For example, a 
researcher could study the protective effect of some medications on different type of 
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cancers by linking NorPD with the Cancer Registry or the negative effect of 
medications used during pregnancy can be studied by linking the Medical Birth 
Registry with NorPD. This feature makes the structure of the health system in Norway 
unique and the epidemiological research very applicable and beneficial. Since the 
establishment ofNorPD, many pharmacoepidemiological studies and reviews have 
been conducted. Since the first publication in 2004, the number of publications has 
increased through the years reaching up to twenty five publications in 2007. 99 In the 
period of 2004-2009, a total of around 50 publications had utilized NorPD. 98 This 
number is expected to increase due to the increased popularity of the database and the 
facilities presented by Norwegian Institute of Public Health. 
Accessing NorPD 
The Norwegian Institute of Public Health facilitates the access ofNorPD for 
researchers who are interested in conducting pharmacoepidemio logical research. The 
researchers can access the data without paying any charges for the data itself The 
researcher will only pay ifthere is any administrative work or file processing that must 
be done in order to obtain the data. In case where statistics related to the medication 
pattern used in Norway, NorPD has a website that includes all information related to 
the database, and from that website, one can create a report related to any variable 
related to medications (http://www.norpd.no/Prevalens.aspx). 93,ioo 
NIPH requires detailed information about the researcher, co-researchers, the 
institute, and the protocol of the study to make sure that the aim of the study is 
compatible with the NorPD's aims. 98 
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Advantages and limitations 
The health system in Norway has many factors that make it one of the most 
unique health systems worldwide. These factors help to establish and maintain 
distinctive databases and registries. It is well known that having a national "social" 
health system is considered an important factor to have an ideal health database. 2'3 
Norway has several advantages pertaining to the databases. It has several databases 
that specialized in areas such as cancer, medical birth, death, and communicable and 
non-communicable disease. Having a specialized database in each area, it is important 
to have a patient's complete and comprehensive data within these specialized 
databases. For instance, the data in the cancer registry is almost 100% complete. 101 In 
addition to having specialized databases, Norway has more than eight databases that 
cover most health areas in addition to medication data. Since most individuals are 
registered within one primary care clinic, most patients have their health information 
in these databases. Therefore, any study done using these databases will be considered 
externally valid (i.e. can be generalized to the Norwegian population) All these 
databases have the eleven-digit p€rsonal identification numbers (person nummer) that 
makes it easy to link all these databases together simply by using this number. 
Therefore, it is possible to conduct different epidemiological researches in different 
areas. In addition, performing a system of monitoring allows researchers to follow the 
trend of the diseases in Norway, and post-marketing surveillances to detect the signals 
for adverse drug reactions as well. Furthermore, it is a relatively inexpensive database 
for researchers to access. 
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Like other countries' databases, Norwegian databases have some limitations. 
The validity of the diagnoses in these databases is not clear. One study found that the 
number of certain diagnoses in these databases are overestimated or underestimated, 
possibly caused by the transition steps that take place until the data reaches the final 
destination. Also, the results of any study used in the Norwegian database are 
generalized to Norwegian population only. Some of these databases have missing 
information; in case ofNorPD, it does not include OTC medications data (except 
prescribed OTC), the indication for use is not mentioned, and the medications 
dispensed to the patients in the hospitals and nursing homes are not available in 
Nor PD. 
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Conclusion 
In conclusion, each database has its own strengths and limitations.NIS can 
answer many research questions related to healthcare utilization and healthcare cost, 
but it is not the best database to answer questions related to medication exposure since 
there is no detailed information about medications. The latter research question can be 
investigated thoroughly and accurately by using the VA databases because these 
databases contain enough data on patient medications. Many other research questions 
can also be answered using VA databases because they have ample data on most 
clinical aspects as well as economic aspects. Pharmacoepidemiologic, 
pharmacoeconomic, and other behavioral studies can be performed using the VA 
databases. However, any study conducted using VA database will only be generalized 
to the VA population. This problem is not a big issue in countries with a social 
healthcare system such as the UK and Norway. The conclusions of studies that use 
the THIN database in the UK can be applied to the entire UK population. This is also 
true of studies that used the Norwegian database. Th~ THIN database shares similar 
characteristics of the VA database in its ability to answer many research questions 
related to diseases and medications. Finally, the Norwegian databases are very 
interesting and well-organized databases. The major strength of these databases is that 
they can be linked together to produce large amounts of patient information to conduct 
many studies. Researchers from inside as well as outside Norway should start to 
utilize these databases. The major difference between U.S databases and European 
databases is a result of the type of healthcare system in each country. As mentioned 
before, the social healthcare system is an ideal environment to produce a good 
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database. This can be found with the THIN database and the Norwegian databases. 
The VA database also has similar attribute because VA health care system somewhat 
resembles a government-run, universal healthcare system. 
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Table 111.1: Essential elements available in nationwide inpatient sample 
Primary and secondary diagnoses 
Primary and secondary procedures 
Admission and discharge status 
Patients demographic data 
Payment resources 
Total charge 
Length of stay 
Hospital characteristics 
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Table 111.2: Areas and topics that can be answered through using nationwide 
inpatient sample database 
Analyses of states and communities 
Health care cost inflation 
Hospital financial distress 
Use and cost of hospital services 
Utilization of health services by special populations 
Medical practice variation 
Medical treatment effectiveness 
Quality of care 
Impact of health policy change 
Access to care 
Diffusion of medical technology 
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Table 111.3: Examples of research questions that can be answered by nationwide 
inpatient sample 
Research question examples Type 
What is the cost of treating asthma? Economic 
What is the epidemiology of meningitis? Epidemiology 
What is the mortality rate in patients treated with Outcome 
thrombolysis? 
Are there racial differences in seeking health care? Access to care 
What is the difference between patients going to teaching Medical practice 
hospital and patients going to other hospitals? 
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Table 111.4: Primary users of nationwide inpatient sample data 
State and federal government agencies Pharmaceutical companies 
Hospital information system firms School of pharmacies, public health 
and business 
Healthcare systems Health services researchers and policy 
analysts 
Health insurance companies Health professions societies 
Hospitals Managed Care Organizations (MCOs) 
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Table 111.5: Advantages and limitations of the nationwide inpatient sample 
database 
Advantages Limitations 
Sponsored by AHRQ Does not include reliable pharmacy 
data 
Largest inpatient database Does not include data outside the 
hospital system 
Inexpensive Race and ethnicity data is incomplete 
Ability to perform analysis of trends over Does not include all hospitals 
time 
Generalizability 
Ability to study rare diseases 
Includes different types of insurance 
sources 
Can be used with different type of 
statistical packages (SAS®, SPSS® and 
Stata®) 
Contains health information as well as 
economic information 
Easy to use 
Contains detailed information about the 
datasets 
Web-based training 
._ 
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Table 111.6: Data sources within Veterans Affairs database 
,...- Description Data source 
r-The National Survey of Veterans Socioeconomic background. 
Military background. 
Health status and healthcare use. 
Veterans' understanding of and use of 
VA benefits. 
VHA Assistant Deputy Under Secretary National statistics on VHA 
for Health (ADUSH) Enrollment expenditures, enrollment, and patients. 
Monthly File 
Beneficiary Identification & Records Death File. 
Locator System (BIRLS) Veterans who have applied for VA 
benefits. 
Veterans discharged from the military 
service since March 1973. 
Recipients of the Medal of Honor 
Service members with accounts for VA 
education benefits. 
VA Decision Support System (DSS) Clinical and financial data for inpatient 
and outpatient care. 
DDS production database that combine 
cost data, clinical data and other data. 
DSS National Data Extracts that include 
several extracts such as Pharmacy, 
Laboratory and other types of extracts. 
The VA-Medicare Data Merge Initiative This initiative sponsored by VA to assist 
the researchers to access Medicare 
database. 
Several Medicare data can be accessed 
such as Medicare Data File 
Documentation, Medicare Current 
Beneficiary Survey (MCBS) and United 
States Renal Data Systems (USRDS). 
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.-The VHA Medical SAS Datasets 
The National Prosthetics Patient 
Database (NPPD) 
The Pharmacy Benefits Management 
(PBM) 
Resident Assessment Instrument -
Minimum Data Set (RAI-MDS) 
It's extracted from the National Patient 
Care Database (NPCD). 
It is the most utilized medical dataset. 
They include all inpatient and outpatient 
care data. 
It developed by the Prosthetic and 
Sensory Aids Service Strategic Health 
Care Group (PSAS). 
It includes information about orthotic, 
prosthetic and sensory devices 
dispensed to veterans nationwide. 
NPPD available since 2000. 
National database that include all 
prescription medications that dispensed 
with VHA system. 
It comprises all inpatient intravenous 
and unit dose prescriptions in VA 
facility and outpatient prescriptions. 
It includes data about dosing 
instructions, National Drug Code 
(NDC), product name, ordering 
provider, quantity dispensed ,drug 
product costs, formulary status, and VA 
drug class 
In includes controlled prescription 
information. 
RAl-MDS defined by VHA as "a core 
set of screening, clinical and functional 
status elements, including common 
definitions and coding categories, that 
forms the foundation of the 
comprehensive assessment for all 
residents of long-term care facilities". 
Data available since 2001. 
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The VA Vital Status files The file comprises the death dates from 
all VA resources. 
It comprises from two files, the master 
and mini files. 
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Table 111.7: The four major datasets in the Medical SAS Inpatient Datasets and 
their definition 
.-Dataset Contained Data 
Main section Data for the patients' inpatient stay. 
Demographics, primary/secondary 
diagnoses and other variables (up to 91 
variables in 2006). 
Bed section Include the patients' data that ·are 
under a specified physician treating 
specialty during the inpatient stay. 
It includes Primary/secondary 
diagnoses and length-of-stay and other 
variables up to 48 variables in 2006. 
Procedure section One day procedure (up to four 
procedures) during the inpatient stay; it 
has up to 25 variables in 2006. 
Surgery section One day surgery (up to 5 surgeries) 
performed in the main or specialized 
room during the inpatient stay; it has 
28 variables in 2006. 
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Table 111.8. Description of the National Data Extracts datasets 
.-NDE Narrative Acronym Availa-
dataset bilty 
Discharge Discharge datasets includes one record for DISCH FY1999-
every hospital stay in a specific fiscal year. 2009 
They were implemented in 1999 and it has 
several variables such as number of X-rays, 
discharge DRG, different type of costs and 
other variables. 
Outpatient Outpatient datasets include services that are OutPat FY1999-
not available in the NPCD. 2009 
They have more detailed cost data and some 
clinical data. 
The files are divided to different group 
because of the big size. 
Treating Treating specialty datasets could have more TRT FY1999-
Specialty than one record for each hospital stay. 2009 
They are divided into different sections 
based on the month and treating specialty of 
the provider for each stay. 
It is associated with the location such as 
medical care, surgical ward or long-term 
care unit. 
Laboratory Laboratory results dataset includes LAR FY2000-
results laboratory results for defined number of 2009 
laboratory tests. 
It has both inpatient and outpatients 
encounters. 
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Labo rat Laboratory datasets include record for every LAB FY2002-
ory individual "patient" laboratory tests for both 2009 
inpatient and outpatient encounter during 
the extract period. 
Radiology Radiology datasets include data such as RAD FY2002-
type, cost and number ofradiological 2009 
procedures that performed in the Diagnostic 
Radiology and Nuclear Medicine 
Departments for every encounter. 
Pharmacy Pharmacy datasets provide data on drugs PHA FY2002-
that used in both inpatient and outpatient. 2009 
They include prescription, unit dose, and IV 
pharmacy detail. 
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Table 111.9: Examples of variables in the Pharmacy National Data Extract 
Variable Definition 
COMP Patient has received the medication by mail. 
DAY_SUPPLY Number of the days' supply for each drug (maximum 180 
days to avoid errors) 
DRUGDESC Drug description 
ACT_COST Actual total cost 
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Table 111.10: Sources of the laboratory and laboratory results National Data 
Extracts 
Source Data Laboratory Laboratory 
result 
VistA Data File (#63) Lab workload 
and the Referral Patient ~ ~ 
File (#67) 
Patient File (#2) and the Patient's demographic 
Referral Patient File data ~ ~ 
(#67) 
VistA Patient Inpatient information 
Movement file (#405) ~ ~ 
V istA Patient Care Encounter information 
Encounter file (e.g. date) ~ ~ 
DSS Cost, product and 
department information. ~ 
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Table 111.11: Examples of numeric value for non-numeric laboratory test results 
.-Non-numeric value Numeric value 
Negative, Non reactive 0 
Positive , Reactive 1 
Borderline results 2 
Test has been done 5 
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r-
Table 111.12: Examples of Laboratory Tests those are available in Laboratory 
datasets 
Laboratory test (Unit) Availability year Result ID number 
Potassium (MEq/L) FY2000 2 
Sodium (MEq/L) FY2000 3 
Blood Urea Nitrogen "BUN" (Mg/dl) FY2000 5 
Creatinine Clearance (Ml/min) FY2000 11 
Digoxin (Ng/ml) FY2000 7 
AST "Aspartate Transaminase" (U/L) FY2000 9 
ALT "Transferase Alanine Amino" (U/L) FY2001 45 
Hematocrit (%) FY2002 50 
INR "International Normalized Ratio" FY2003 52 
Creatinine GFR (ML/MIN/1. 73M2) FY2006 66 
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Table 111.13: Advantages and limitations of the VA databases 
Advantages Limitation 
Largest database in the US Majority are male 
National database Contains variables reported by patients 
such as using illicit drug 
Includes most of the information that Smoking status is not well documented 
required to conduct a research (i.e. 
diseases, medications, laboratory, 
radiology, all patient demographics .. etc) 
Most of the databases are free to access 
Uses single unique identifier to lin dataset 
in fiscal year 
Most diseases' definition by ICD-9 have 
been validated 
Many measures are taken to guarantee the 
patient privacy 
Help and technical support is very active 
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Table 111.14: Some variables in the THIN database and their original sources 
Variable Original source* 
Patient identifier (Patid) All files 
Age Patient file 
Sex 
Death date 
Event date Medical file 
Read medical code 
Hospital referral 
Medical history 
Prescription date Therapy file 
Drug code (multilex code) 
BNF codes 
Dosage and duration of prescription 
Height Additional Health Data (AHD) file 
Weight 
Vaccination 
Smoking and alcohol intake 
Pregnancy and birth details 
Laboratory tests and their results 
*Some variables can be found in more than one source. 
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Table 111.15: Examples of READ codes in the THIN database 
Read code Description 
D21z Anemia 
G33 Angina pectoris 
M03z000 Cellulitis Not otherwise specified (NOS) 
FOO .. Bacterial meningitis 
713 .. Breast operations 
535 .. Standard chest X-ray 
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Table 111.16: Examples of British National Formulary (BNF) drug codes in the 
THIN database 
BNF code Drug name Therapeutic group 
05.01.0 l.03a Amoxicillin Broad spectrum 
penicillins 
06.02.0 l .OOa Levothyroxine Thyroid hormones 
02.04.00.00b Bisoprolol Beta-Blocker 
02.06.01.00a Glyceryl Trinitrate Nitrates 
07.03.02.0lc Levonorgestrel Oral progestogen-only 
contraceptives 
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Table 111.17: Advantages and limitations of the THIN database 
Advantages Limitations 
Computerized Generalized to UK population only 
Population-based Not fully completed 
Longitudinal Costly 
Large number of patients 
Validated 
Access the original medical record 
Confidentiality 
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Table 111.18: Examples of databases available in Norway 
Database Description 
The Cause of Death Register 90 - Includes the cause of death data since 
1922. 
- It used to publish statics about the 
causes of death annually. 
- It has different information in addition 
to the underlying cause of death like 
age, gender, region of the person and if 
it is suicide or not. 
- It has information about death due to 
alcohol narcotics and medications. 
- It runs by statistics Norway with a 
cooperation with the Norwegian Institute 
of Public Health 
The Cancer Registry of Norway 90•91 - The purpose of this registry is to prevent 
the caner by knowing the reasons that 
cause cancer and most common cancers, 
to have a real statistics about the number 
of cancer cases and the distribution of 
these cases among Norwegian 
population and to have a good resource 
to conduct epidemiological researches 
re lated to cancer. 
- It has all cancer cases since 1953 to date 
and it has over 500,000 cancer cases. 
- It has a statistics about the major 
common cancer types among men and 
women. 
- The reporting system to this registry is 
consider of very complete (near to 
100%) 
- Patients can be linked using their unique 
personal identification number 
The Medical Birth Registry of Norway 90•102 - The aim of this registry is for 
conducting surveillances about the 
newborn babies' health and the 
pregnancy outcomes and to conduct 
epidemiological researches related to the 
babies' health and to pregnancy 
outcomes. 
- It is a national registry in Norway and 
includes all babies born there. 
- It has all babies' data since 1967 
therefore, it considered the world's first 
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medical birth registry 
- Can be linked with other registries in 
Norway so it a great resource for 
research in combined with other 
registries 
- The registry is responsible by the 
Norwegian Institute of Public Health and 
the University of Bergen 
The Norwegian Surveillance System for - MSIS has data about all infectious 
Communicable Diseases (MSIS) 90'103' 104 diseases at national and local level. 
- It is the official monitoring system for 
communicable diseases in Norway. 
- The sources of MSIS are from 
physicians, hospitals and laboratories. 
- The information include; disease name, 
month and year of diagnosis, age group 
of the patient, county ofresidence and 
place of the infection and the mode of 
transmission in case of HIV, syphilis, 
gonorrhea and viral hepatitis. 
- MSIS is responsible by the Norwegian 
Institute of Public Health 
The Tuberculosis (T.B) Registry 9o,10s,106 
- It is responsible by the Norwegian 
Institute of Public Health under department 
of infectious disease epidemiology. 
- It has all TB cases since 1962 
- All counties in Norway are required to have 
TB control program. 
- All the cases data should be send to the 
Tuberculosis Registry 
- The aim of the registry is to detect early TB 
cases and treat it and to conduct 
epidemiological research related to TB 
disease. 
- The sources of the registry are physicians, 
antituberculosis prescriptions and 
laboratory. 
- It has important variables such as; patient 
age, gender, site of the disease and birth 
place. 
The Childhood Vaccination Register (SVSVAK) - The aim of the registry is to make sure 
90 that all children are vaccinated and to 
conduct researches related to vaccines. 
- All centers are required to register the 
child ' s immunizations to the registry. 
- It also used to monitor the adverse effect 
of the immunizations. 
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- It is under the department of vaccine 
and immunity at t the Norwegian Institute 
of Public Health 
- It has information about the child such as 
child name, unique identification personal 
number, family address, vaccine name 
and vaccination date and any adverse 
events. 
The National Injury Register (NIR) 90'91 - It is responsible by the Norwegian 
Institute of Public Health 
- It was established in 1985 and it has all 
injury cases till now. 
- NIR are using other register as 
references such as The National 
Register of Deaths, The National 
Hospital Discharge Register and The 
National Injury Sample Register. 
- The variables in NIR include age, sex, 
place of residence, type of accident, 
mechanism of injury, type and severity 
of injury, product involved, time and 
event of injury and the medical 
information on the site. 
- The aim of NIR is to have information 
about the number and type of in juries 
for statistics and prevention purposes 
and to conduct epidemiological 
research. 
Database over Occupational Injuries and - It was established in 1990. 
Occupational Diseases 91 - It is responsible by the Association of 
Norwegian Insurance Companies. 
- It includes all Occupational Injuries and 
Occupational Diseases that reported to 
the insurance companies. 
- The variables are unique identification 
personal number, degree of disability, 
types of contact, the part of body 
injured, item caused the injury, the 
diagnoses "for occupational diseases" 
and the worker's compensation. 
- The aim of the registry is to use the 
information in the database for 
prevention purposes and for research 
purposes. 
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Table 111.19: Resources for Norwegian Health Information System ("Norhealth") 
Source name 
Cause of Death Register 
Medical Birth Registry ofNorway 
Tuberculosis Registry 
Norwegian Patient Register 
Statistics Norway' s Health Interview Survey 
Cancer Registry of Norway 
Norwegian Prescription Database 
Norwegian Surveillance System for Communicable Diseases 
Childhood Vaccination Register 
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Table 111.20: Aims of the Norwegian Prescription Database (NorPD) 
To explain the pattern of medication utilization and monitor the trends of utilization 
over time 
To function as a base resource for drug related statistics to be used by authorities to 
assess the quality of drug prescription, controlling and planning 
To function as an internal control for prescribers to improve the quality of prescribing 
practice. 
To function as the main resource for medication and pharmacoepidemiological 
research. 
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Table 111.21: Variables available at Norwegian Prescription Database (NorPD) 
Element 
Patient 
Prescriber 
Drug 
Pharmacy 
Variables 
- Encrypted personal identification 
number 
- Gender 
- Date of birth 
- Place of residence 
- Date of death 
- Encrypted personal identification 
number 
- Gender 
- Date of birth 
- Profession 
- Specialty 
- Drug brand name, strength , package 
size and number of package 
- ATC code and DDD 
- Category of prescription 
- Code of reimbursement 
- Date of Dispensing 
- Drug cost 
- Area of a_QQ_lication and prescribed dose 
- Pharmacy name 
- License number 
- Place of pharmacy (municipality and 
counb') 
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